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Abstract
Well-established in the field of bioelectronic medicine, Spinal Cord Stimulation (SCS) offers an 
implantable, non-pharmacologic treatment for patients with intractable chronic pain conditions. 
Chronic pain is a widely heterogenous syndrome with regard to both pathophysiology and the 
resultant phenotype. Despite advances in our understanding of SCS-mediated antinociception, 
there still exists limited evidence clarifying the pathways recruited when patterned electric pulses 
are applied to the epidural space. The rapid clinical implementation of novel SCS methods 
including burst, high frequency and dorsal root ganglion SCS has provided the clinician with 
multiple options to treat refractory chronic pain. While compelling evidence for safety and 
efficacy exists in support of these novel paradigms, our understanding of their mechanisms of 
action (MOA) dramatically lags behind clinical data. In this review, we reconstruct the available 
basic science and clinical literature that offers support for mechanisms of both paresthesia spinal 
cord stimulation (P-SCS) and paresthesia-free spinal cord stimulation (PF-SCS). While P-SCS has 
been heavily examined since its inception, PF-SCS paradigms have recently been clinically 
approved with the support of limited preclinical research. Thus, wide knowledge gaps exist 
between their clinical efficacy and MOA. To close this gap, many rich investigative avenues for 
both P-SCS and PF-SCS are underway, which will further open the door for paradigm 
optimization, adjunctive therapies and new indications for SCS. As our understanding of these 
mechanisms evolves, clinicians will be empowered with the possibility of improving patient care 
using SCS to selectively target specific pathophysiological processes in chronic pain.
Keywords
Spinal cord stimulation; Biomarker; Neurophysiology; Chronic pain; Complex regional pain 
syndrome; Failed back surgery syndrome; Mechanisms of action; Neuropathic pain; Objective 
measures; Neuroinflammation
Background
Chronic Pain is a heterogenous, complex syndrome with significant burden for both the 
patient and the healthcare system. While the advent of multi-modal and multidisciplinary 
treatment approaches has improved strategies for chronic pain management, the push for 
opiate-free therapies has inspired development of novel approaches to both nociceptive and 
neuropathic pain syndromes. The gate-control theory of pain proposed by Melzack and Wall 
in 1965 spurred development of conventional Spinal Cord Stimulation (SCS), first surgically 
implanted in 1967 by Shealy, who noted that paresthesia elicited by electrical stimulation of 
the dorsal columns (DC) inhibited deep pain due to metastatic lung cancer (Melzack & Wall, 
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1965; Shealy et al., 1967). This groundbreaking work into the field of bioelectronic 
medicine ultimately opened the door for SCS and the rise of targeted neuromodulation.
SCS has been successfully utilized over the last half century in the adjunctive treatment of 
refractory pain syndromes not amenable to conservative therapy. Though the gate-control 
theory initially postulated a reduction in nociceptive pain in response to SCS, clinical 
experience demonstrated that patients with neuropathic and other rarer pain syndromes also 
received benefit. Current indications for SCS include Failed Back Surgery Syndrome 
(FBSS), Chronic Regional Pain Syndrome (CRPS), neuropathic pain, visceral abdominal 
pain and intractable angina pectoris (Lindblom & Meyerson, 1975; Linderoth & Foreman, 
2017). While paresthesia-based SCS (P-SCS) now represents the traditional approach to 
neuromodulation of these dysregulated pain pathways, novel SCS paradigms and new 
anatomical targets have rapidly entered clinical use in the field of bioelectronic medicine. 
These include Dorsal Root Ganglion stimulation (DRG-S) as well as the paresthesia-free 
SCS (PF-SCS) paradigms: Burst SCS (B-SCS) and High Frequency SCS (HF-SCS). An 
additional PF-SCS paradigm, Evoked Compound Action Potential SCS (ECAP-SCS) has 
recently been developed, utilizing closed-loop monitoring to improve charge delivery to 
spinal targets. Together, the rapid clinical implementation of these novel paradigms has 
outpaced the bandwidth of the preclinical sciences to decipher the mechanisms and recruited 
pathways responsible for their efficacy. While some work has been completed, the trajectory 
of this ascension has left a sizeable knowledge gap between the basic sciences and clinical 
research, necessitating a review of evidence and theory for the mechanisms of action of 
these devices. In this review, we will 1) elucidate pertinent dysregulated pathways 
responsible for chronic pain syndromes, 2) identify the neuroanatomical targets thought to 
be modulated by SCS paradigms, 3) discuss proposed mechanisms of P-SCS, PF-SCS, 
DRG-S, and ECAP-SCS, and 4) present and evaluate the preclinical and clinical evidence in 
the context of these proposed mechanisms. Collectively, this review serves to recognize gaps 
in current knowledge and identify potentially rich avenues for future investigation.
Parameters for spinal cord stimulation
Prescribed by the device generator, the implanted SCS leads deliver a charge “dose” to the 
target tissue. This generates a local electric field (EF). Neural bodies, synapses and axons 
which project through the EF may be modulated (Miller et al., 2016). While leads from P-
SCS and PF-SCS enter the epidural space and deliver charge to the midline structures, DRG-
S leads enter the epidural space, exit the neuroforamina and deliver charge to the adjacent 
DRG (Fig. 1) (Miller et al., 2016). The fundamental unit of a SCS program is the pulse, 
which is defined by the amplitude, pulse width (PW) and delivery waveform (Fig. 2, Panel 
a). By convention, frequency describes the number of pulses within one second (Miller et 
al., 2016). B-SCS utilizes a novel firing pattern, wherein stacked pulses are delivered 
followed by a period of quiescence which is then repeated. Thus, B-SCS can also be defined 
by intra-burst frequency and inter-burst frequency (Fig. 2, Panel b) (Chakravarthy et al., 
2018a). Parameters for SCS charge delivery are reviewed in Fig. 2.
Lead impedance represents the inherent resistance of tissue to changes in charge. In SCS, the 
impedance is determined by the interaction between the lead contact and target, which may 
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vary in an acute or chronic manner. Acute alterations in impedance reflect alterations in the 
anatomic relationship of the lead to the DC. These include lead migration, spine position 
such as lumbo-thoracic extension or abrupt changes in cerebrospinal fluid (CSF). Also 
caused by CSF volume expansion, local tissue fibrosis and scarring are thought to contribute 
more significantly to chronic elevations in impedance (Abejon & Feler, 2007). Interestingly, 
Kramer et al. (2015) noted these impedance changes are mitigated with close lead contact 
and use of the relatively immobile DRG-S (Kramer et al., 2015). The charge delivery 
strategy determines whether voltage or current will be fixed in relation to the system’s 
impedance (Fig. 2, Panel c). In current-controlled (CC) systems, the current is set; variations 
in impedance cause a change in voltage. In voltage-controlled (VC) systems, the voltage is 
set; variations in impedance cause a change in current (Miller et al., 2016; Schade et al., 
2010). These systems will deliver a pulse with either constant voltage or constant current for 
a specified period of time (PW). The repolarization waveform is determined by the charge-
balancing (CB) strategy (Fig. 2, Panel c) (Miller et al., 2016). Active CB creates a 
symmetric, biphasic pulse. Passive CB yields an asymmetric pulse. In either CB strategy, the 
initial pulse is followed by equal and opposite current movement to return the net charge to 
baseline; this avoids buildup of charge in the tissue, which may lead to injury if allowed to 
accumulate (Miller et al., 2016).
In response to a single pulse, axons and cell bodies within the EF exhibit a spectrum of 
modulation including no change, sub-threshold depolarization or generation of a mature 
action potential (AP). Intermittent, repeated pulses can induce summative APs. The 
susceptibility of fibers to depolarization is dependent on fiber thickness, myelination and 
distance from the lead. This susceptibility is summarized by each fiber’s strength-duration 
curve. As the total charge delivery of each pulse is the product of amplitude and PW, this 
curve represents total charge delivery necessary for AP generation (Abejón et al., 2015; West 
& Wolstencroft, 1983). Central to the perception of paresthesia in P-SCS, threshold 
depolarization of a DC Aβ fiber generates an AP, which may travel in an orthodromic and 
antidromic manner (West & Wolstencroft, 1983; Holsheimer, 2002). The coverage and 
intensity of paresthesia produced by P-SCS are determined by the amplitude and PW. Higher 
amplitude currents or voltages provide stronger paresthesia. Increasing the PW leads to 
greater fiber recruitment and increases the distribution of paresthesia (Holsheimer, 2002; Lee 
et al., 2011; Hershey et al., 2010). Frequency also plays a role in determining PW, as they 
are inversely related: as frequency increases, the available PW decreases. Additionally, as 
neurons intrinsically have maximal firing frequencies due to refractory periods, providing an 
overdriving stimulus would not allow every threshold pulse to generate an AP. 
Neuromodulation can occur without generating a paresthesia when the generated pulse is 
below the AP threshold of the fiber, as in PF-SCS paradigms that utilize properties of the 
strength-duration curve. The shape of this inverse hyperbolic curve can be exploited such 
that very large quantities of charge can be delivered without generating a paresthesia-
evoking AP, especially at the extremes of PW and amplitude (Miller et al., 2016; Hershey et 
al., 2010). Subthreshold depolarizations by a weak EF are postulated to modulate neural 
networks by causing firing desynchrony, AP inhibition and changes in the resting membrane 
potential (Miller et al., 2016). Novel PF-SCS such as HF-SCS utilizes a charge delivery 
strategy such that a single, limited DC AP is generated only when PF-SCS is initiated, 
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though no paresthesia is reported by the patient. These paradigms likely provide analgesia 
through novel mechanisms which remain to be elucidated and will be reviewed in their 
respective sections (Crosby et al., 2016). Despite advances in P-SCS and PF-SCS program 
settings, the common basis for classification of SCS remains frequency, with the exception 
of DRG-S which is an anatomic specification, and ECAP-SCS, which is a novel program 
(Miller et al., 2016). While this makes device categorization simple in colloquial contexts, in 
reality all pulse parameters must be considered to influence the physiologic response to SCS 
(Miller et al., 2016). Below, we will discuss the dysregulated pain pathways thought to be 
modulated by the charge delivery of SCS.
Mechanisms of hyperalgesia and allodynia
Pain is a context-dependent sensory or emotional experience associated with actual or 
potential damage to tissue. A peripheral nociceptive stimulus is perceived via pathways 
projecting to cortical and subcortical regions, resulting in the conscious and affective pain 
experience. Chronic pain is a product of the dysregulation in pain processing in response to 
peripheral or central injury. Serving to guide clinical therapies, preclinical models attempt to 
recreate these dysregulated pain pathways, further our understanding of antinociceptive 
mechanisms and have spurred the development of novel SCS paradigms. Animal models of 
hyperalgesia and allodynia include chronic constriction injury (CCI), spinal nerve ligation 
(SNL) and spared nerve injury (SNI); these models generate an incomplete nerve injury 
representative of typical human pathology, in opposition to complete transection models 
(Todd, 2010). SNI and SNL animals develop tactile allodynia within the first day, whereas 
CCI animals develop allodynia over the course of one week. The target of the CCI and SNI 
models are the sciatic nerves whereas SNL targets the L4/L5 spinal nerves (Todd, 2010). 
Measuring paw withdrawal thresholds (PWT) to evaluate pain behavior before and after 
intervention, animal models are routinely employed in the assessment of SCS paradigms and 
elucidation of their respective mechanisms. At the crux of chronic pain pathogenesis is 
central sensitization (CS), which the IASP Task Force defines as “increased responsiveness 
of nociceptive neurons in the central nervous system (CNS) to normal or subthreshold 
afferent input” (Sandkuhler, 2010; Taxonomy ITFo, 1994). Peripheral injury leads to 
pathologic activation of post-synaptic nociceptive projection neurons (PN) and has become 
the focus of research in animal models (Sandkuhler, 2009). SCS-mediated pain relief is 
thought to act through modulation of the maladaptive aggregate response to local injury, 
neuroinflammation and CS at both the segmental and supraspinal levels, processes which are 
hallmarks of hyperalgesia and allodynia. The ligand-receptor pairs of interest to the process 
of CS include: 1) Glutamate, which activates N-methyl-D-aspartate (NMDA), amino-3-
hydroxy-5-methyl-4-isoxazole propionate (AMPA), and metabotropic glutamate (mGLU) 
receptors (Todd, 2010; Latremoliere & Woolf, 2009), 2) Substance P (SP), which activates 
Neurokinin-1(NK1) Receptors (Latremoliere & Woolf, 2009), 3) Brain-derived neurotrophic 
factor (BDNF) which activates Tropomyosin receptor kinase B (TrkB) receptor 
(Latremoliere & Woolf, 2009), 4) Calcitonin Gene-related Peptide (CGRP) which activates 
CGRP Receptor, 5) Gamma-aminobutyric Acid (GABA) which activates GABA Receptors, 
including the GABA A (GABAA) Receptor and GABA B (GABAB) Receptor and 6) 
Glycine (Gly) which activates the Gly Receptor (GlyR).
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CS is thought to result as a consequence of changes to the neuroactive milieu and post-
synaptic receptor activation state. Pathologic nociception develops after CS through long-
term potentiation (LTP), loss of spinal inhibition, neural plasticity and phenotypic 
transformation of low-threshold Aβ afferents (Todd, 2010). Windup represents the short-
term, reversible temporal summation of slow C-fiber activation of NK-1 and CGRP 
receptors, leading further to NMDA receptor activation and prolongation of progressive 
membrane depolarization (Latremoliere & Woolf, 2009). Though windup is commonly 
ascribed to the pathogenic process of CS, LTP produces durable activation changes of the 
NK1-positive PN. Repetitive stimulation of NK1 positive neurons leads to synaptic 
amplification through a Ca2+-dependent mechanism (Latremoliere & Woolf, 2009; Ikeda et 
al., 2006). Implicated in CS, repetitive stimulation leads to elevations in intracellular 
calcium. Activation of Ca2+-dependent protein kinases leads to receptor ionophore 
phosphorylation and decreased potassium currents, resulting in increased receptor efficacy 
and potentiation of AMPA, NMDA and NK1 signaling (Sandkuhler, 2009; Latremoliere & 
Woolf, 2009). Similar to excitatory LTP, nerve injury can also result in dysregulation of 
inhibition, primarily through a functional loss of GABA signaling. Moreover, after nerve 
injury, PN may become altered so that GABAA and glycine receptor signaling becomes 
excitatory. As chloride ionophores, GABAA and glycine receptors facilitate Cl− movement 
across its transmembrane gradient, which is maintained by active Cl− transporters. Noted 
after nerve injury, a reduction in Cl− exporter function yields an increase in intracellular Cl− 
concentration (Benzon et al., 2014). Transmembrane gradient reversal may lead to 
paradoxical AP generation with the activation of GABAA and glycine receptors, whereby an 
initially inhibitory or non-noxious stimulus now generates a nociceptive AP (Benzon et al., 
2014). This mechanism, in part, also explains the paradoxical nociceptive response to Aβ 
drive, while pathological ectopic Aβ sprouting also contributes (Benzon et al., 2014). While 
the pathogenesis of CS is a heterogenous process, changes in receptor kinetics leading to 
sub-threshold and paradoxical AP generation are one explanation for hyperalgesia and 
allodynia (Fig. 3). Paramount, modulation of CS at the segmental level remains the 
mechanistic cornerstone of analgesia from SCS. In the non-pain state, inhibitory 
interneurons release GABA and glycine to suppress post-synaptic depolarization through Cl
−
 dependent hyperpolarization (Benzon et al., 2014). In nerve-injury models, loss of 
GABAergic positivity in the dorsal horn (DH) has been observed with CS, due to cell death 
or the depletion of GABA in terminals (Moore et al., 2002; Polgar et al., 2003). GABA 
depletion is known to play a significant role in CS, as allodynia is reduced with intrathecal 
GABAA receptor agonism and induced by nonspecific GABA receptor antagonism (Hwang 
& Yaksh, 1997; Malan et al., 2002). Whereas GABA depletion, receptor potentiation and 
ionophore kinetics offer competing hypothesized mechanisms of hyperalgesia and allodynia, 
the CS phenotype is likely oversimplified in clinical practice (Fig. 3).
Reorganization and phenotypic transformation of mechanoreceptive Aβ afferents also plays 
a role in the pathogenesis of CS. Woolf et al. (1992) demonstrated that the central terminals 
of Aβ afferents, normally projecting to laminae III and IV, sprouted to lamina II after 
axotomy (Woolf et al., 1992). This arborization of nonnociceptive, low-threshold myelinated 
inputs to lamina II primarily populated by nociceptive terminals likely also contributes to 
tactile allodynia after nerve injury (Woolf et al., 1992). Moreover, Aβ afferents began 
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expressing SP after nerve injury, thought to contribute to allodynia (Fig. 3, Panel b) (Hughes 
et al., 2007; Neumann et al., 1996). Lastly, abnormal polysynaptic circuits may lead to the 
miscoding of a mechanoreceptive input as nociceptive (Schoffnegger et al., 2008). While 
initially it was thought that SCS activation of Aβ afferents would inhibit ascending 
nociceptive inputs through the simplified gate-control mechanism, it is now clear that 
additional mechanisms at the segmental and supraspinal levels play a role in SCS-mediated 
analgesia. Offering an explanation for the variable response to SCS, seemingly similar 
clinical phenotypes may be generated by vastly different pathologic mechanisms, explained 
by the heterogenous, maladaptive process of central sensitization.
Neuroanatomical targets of spinal cord neuromodulation
Spinothalamic tract
A functional understanding of the spinothalamic tract (STT) is critical to evaluating 
mechanisms of SCS-mediated analgesia. AP originating from the stimulation of peripheral 
nociceptors are transmitted to the CNS via the thinly myelinated Aδ and unmyelinated C 
fibers (Benzon et al., 2011). Aδ fibers, conducting at a moderate velocity of 5–10 m/s, 
synapse in Rexed laminae I and III-V of the spinal cord DH (Benzon et al., 2011). As Aδ 
fibers conduct more quickly than C fibers, they are considered the first pain signal, carrying 
acute pain, temperature and pressure (McMahon et al., 2013). C fibers, conducting at a 
slower velocity of < 2 m/s, synapse superficially in Rexed laminae I-II. AP to C fibers are 
initiated by multiple receptor types, including thermoreceptors, mechanoreceptors and 
chemoreceptors; thus these fibers are classified as polymodal (Todd, 2010). C fibers carry 
the delayed pain response, often characterized as poorly-localized burning or aching. By 
synapse quantity, Aδ and C fibers primarily project to interneuron circuitry, which serves as 
a conduit to conduct inhibitory or excitatory signals to ascending PN (Polgar et al., 2008). 
However, primary afferents also synapse directly on two types of second-order PN: 
multimodal Wide Dynamic Range (WDR) neurons and Nociceptive Specific (NS) neurons 
(Todd, 2010; McMahon et al., 2013). WDR neurons, concentrated in laminae III-V, receive 
input from interneurons of Aβ, Aδ and C fiber origin (Todd, 2010; McMahon et al., 2013). 
Because they receive inputs from both noxious and non-noxious stimuli, it is fitting that 
WDR neurons have a graded increase in firing frequency and amplitude with repetitive 
polymodal stimuli (Mendell, 1966). NS neurons, concentrated superficially in laminae I-II, 
only receive input from fibers carrying noxious stimuli and do not exhibit a graded response 
to pain stimuli. Moreover, stimulation of independent sympathetic neurons shows significant 
activation of WDR neurons while NS neurons are not as impacted (Roberts & Foglesong, 
1988). Axons of WDR and NS neurons carrying crude touch, pain and temperature 
decussate and ascend in the anterolateral STT, synapsing on nuclei in the posterior, medial 
and lateral thalamus. Collateral axons ascend and project onto centers for autonomic 
regulation and somatosensory modulation within the brainstem and midbrain. A functional 
understanding of this tract is critical to evaluating SCS mechanisms as it serves as the 
primary modulatory target via both segmental spinal and supraspinal mechanisms.
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Dorsal column - medial lemniscus pathway
Though responsible for the paresthesia induced by direct stimulation in P-SCS, the DC 
normally carry fine touch, vibration and proprioceptive afferent inputs from peripheral 
mechanoreceptors (Todd, 2010). These peripheral APs enter the spinal cord via axons of 
pseudou-nipolar neurons at the DRG and ascend in the DC via the dorsal column medial 
lemniscus (DCML) pathway. As discussed previously, Aβ fibers also send inputs to circuits 
of the DH, affecting afferent nociceptive AP and contribute to CS. First order fibers 
ascending in the DCML then synapse on their respective nuclei within the ipsilateral 
medulla: the upper extremities synapse in nucleus cuneatus laterally, whereas the lower 
extremities synapse on the nucleus gracilis medially (McMahon et al., 2013). Second order 
axons decussate in the brainstem forming the internal arcuate fibers, then ascend cephalad 
through the brainstem and midbrain in the medial lemniscus, acquiring trigeminal inputs, 
ultimately synapsing on the Ventral Posterior Lateral (VPL) and Ventral Posterior Medial 
(VPM) nuclei of the thalamus. Third and higher order neurons carrying inputs from the 
DCML and STT project to the somatosensory cortex (McMahon et al., 2013). While the 
stimulation of DC Aβ fibers activates DH inhibitory circuits in an antidromic manner (Fig. 
4), other important mechanisms contribute to SCS-mediated analgesia (Fig. 5).
Native signal modulation: beyond gate control
The origins of Melzack and Wall’s gate-control theory of pain developed from the 
hypothesis that cells of the substantia gelatinosa (SG) played a role in presynaptic inhibition 
of cutaneous sensory input (Mendell, 2014). Based on their input mapping and the discovery 
of axo-axonal synapses, Szentagothai (1964) postulated that spinal interneurons played a 
role in modulating ascending nociceptive signals (Mendell, 2014; Szentagothai, 1964). 
Specifically, they hypothesized the existence of a single interneuron with inhibitory input to 
the small and large fiber terminals; this interneuron itself received stimulatory input from 
large fibers (Aβ) and inhibitory input from small fibers (Aδ and C) (Melzack & Wall, 1965; 
Mendell, 2014). Central to this theory, they postulated that an imbalance between small and 
large fiber input could lead to disinhibition of the WDR neuron, thus leading to transmission 
of the ascending pain signal. Support for this model was provided by experiments 
demonstrating presynaptic control in the SG by stimulating small or large fibers and 
measuring evoked dorsal root potentials (Mendell, 2014). Though the gate control theory of 
pain continues to serve as a simplified model for framing pain signaling, it is current cannon 
that many additional factors contribute to spinal nociceptive modulation. Relevant to SCS-
mediated analgesia, local interneurons, descending projections, glia and neuroinflammation 
comprise the contributing SG architecture to nociceptive processing (Fig. 4).
Spinal interneurons
Inhibitory and excitatory interneurons play an important role in the sensory signaling 
cascade, modulating the activity of WDR and NS neurons in the DH. Adding to Melzack 
and Wall’s gate-control theory, interneurons form an adaptive neural circuitry critical in 
modulation of afferent nociceptive signaling that establishes a balance between excitatory 
and inhibitory inputs. Laminae I-III of the DH are populated with a plexus of interneurons 
(Todd, 2010). Excitatory interneurons secreting glutamate comprise the non-GABAergic 
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interneurons of laminae I-III, identified by immunostaining at the synaptic bouton (Todd, 
2010; Todd et al., 2003). GABA and glycine immunostaining in the rat DH exposed a dense 
plexus of inhibitory axons that largely arise from local interneurons in laminae I-III (Polgar 
et al., 2003; Todd & Sullivan, 1990). As evidence for circuit plasticity, Keller et al. (2001) 
has demonstrated that inhibitory synapses undergo maturation and tuning through 
refinement of neurotransmitter release (Keller et al., 2001). Potentially, SCS-mediated 
analgesia contributes to restoration of non-pathologic equilibrium in this inherently plastic 
circuitry (Saadé et al., 2006; Lind et al., 2016). Attenuation of WDR neuron 
hyperexcitability through Aβ-mediated inhibitory control is one proposed mechanism of P-
SCS analgesia (Simone et al., 1991; Willis et al., 1974; Chung et al., 1979). Careful 
neuroanatomical studies show that both SG interneurons and WDR PN are involved in 
GABAergic synapses (Todd, 2010; Zeilhofer et al., 2012; Lekan & Carlton, 1995). Single 
unit recording studies show dorsal column stimulation inhibits WDR neuron hyperexcitation 
within the DH deep laminae (Hillman & Wall, 1969; Lindblom & Meyerson, 1975; Foreman 
et al., 1976; Linderoth et al., 2009; Zhang et al., 2014). Critically, P-SCS applied to the DC 
prevented WDR sensitization secondary to C Fiber-induced LTP and wind-up (Wallin et al., 
2003; Guan et al., 2010). Moreover, it has been observed that P-SCS inhibits WDR neuron 
activation in animal models of neuropathic pain (Yakhnitsa et al., 1999). Numerous 
preclinical studies have confirmed that Aβ fiber suppression of neuropathic pain is mediated 
through a GABAergic mechanism (Sivilotti & Woolf, 1994; Duggan & Foong, 1985). While 
studies demonstrating the effects of SCS on GABAergic inhibitory interneurons are 
reviewed in depth in the ‘gamma-aminobutyric acid’ section, it should be noted that 
suppression of PN firing by P-SCS is dependent on intact cord architecture and lead 
proximity (Hillman & Wall, 1969; Foreman et al., 1976; Smits et al., 2012). Taken together, 
there is strong evidence for segmentally-mediated DH regulation of nociception, either 
through potentiation or inhibition of PN by local interneurons. The relative contribution of 
segmental and supraspinal antinociceptive mechanisms mediated by either P-SCS or PF-
SCS remains an intense area of research.
Descending Antinociceptive systems
Paresthesia based spinal cord stimulation provided the first clear evidence that SCS activates 
the descending antinociceptive system (DAS), thus modulating the DH and PN. First, 
Nashold et al. (1972) suggested that SCS masked pain at the supraspinal level based on data 
showing that DC stimulation produced measurable EEG potentials consistent with known 
somatosensory evoked potentials (Nashold et al., 1972). While investigating local 
mechanisms of SCS, Foreman et al. (1976) further suggested presence of a supraspinal 
mechanism given that mid-thoracic and cervical stimulation depressed spinothalamic tract 
activity measured at the lumbosacral enlargement (Foreman et al., 1976). Clarifying 
supraspinal control over DH PN firing, Saade et al. (1985) utilized DC-transected 
decorticate-decerebrate cats, showing that DC stimulation rostral to the transection as well 
as direct stimulation of nucleus raphe magnus inhibited firing in DH neurons (Saade et al., 
1985). Expanding on this observation, their group used carefully-designed brainstem 
lesioning experiments to elucidate the connections between the DC, periaqueductal gray 
(PAG) and nuclei of the reticular formations (Fig. 5) (Saade et al., 1982; Saade et al., 1983). 
In subsequent investigations in which they stimulated only the DC nuclei, their group 
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confirmed a supraspinal inhibitory loop in an awake rat model (Saade et al., 1986). These 
studies accelerated the interest into DAS as exploitable mechanisms of SCS (Fig. 5).
Colloquially termed the serotonergic DAS, inputs to the PAG relay through the rostral 
ventromedial medulla (RVM), descend in the dorsal lateral funiculus (DLF) and project to 
interneurons of the DH (Fig. 5). While the serotonergic DAS largely utilizes the 
neurotransmitter serotonin (5-HT), opioidergic and GABAergic mechanisms contribute at 
the supraspinal and segmental levels (Cui et al., 1999). The PAG, a well-known opioidergic 
pain center, does not have direct projections to the DH, and instead relays its descending 
signals through the RVM (Behbehani & Fields, 1979). A spinal relay for all descending non-
noradrenergic pain inhibition, the RVM is comprised of the nucleus raphe magnus and 
nuclei of the reticular formations (Newman, 1985). Both the PAG and RVM receive 
ascending inputs from DH PN, creating a feedback loop (Dong et al., 1999; Hardy, 1986; 
Helmstetter et al., 1998; Sakata et al., 1989). The PAG and RVM are highly innervated by 
pain modulating centers, receiving projections from cortical and subcortical structures, thus 
contributing the conscious, stress and emotional responses to pain (Dong et al., 1999; Hardy, 
1986; Helmstetter et al., 1998; Sakata et al., 1989). Together, these supraspinal cortical and 
subcortical communications comprise the neural signature of pain, which will be evaluated 
in the context of P-SCS and PF-SCS in the ‘SCS affects Cortical and subcortical pain 
processing’ section.
Fibers from the RVM descend via the DLF to widely innervate the DH (Todd, 2010; 
Basbaum et al., 1976). RVM cells projecting to the DH have multiple classifications: ON, 
OFF, 5-HT like or neutral. While neutral cells and 5-HT like cells have only been partially 
characterized, more is understood about the firing patterns of ON and OFF cells (Fields, 
2004). Normally quiescent, ON cells are activated by a nociceptive stimulus, enhancing DH 
nociceptive transmission (Mendell, 2014). Pathologic ON cell activity is thought to play a 
role in CS and opioid-induced hyperalgesia (Mendell, 2014). Tonically suppressing DH pain 
transmission, pathological OFF cell deactivation leads to increased pain transmission in the 
DH. Their activity enhanced by opioids, RVM OFF cell regulation of the nociceptor-PN 
synapse creates an opioid-dependent supraspinal pain gate (McMahon et al., 2013; Mendell, 
2014). In the RVM, exogenously administered opioids activate OFF cells and suppress ON 
cells through a GABAergic mechanism (McMahon et al., 2013). Sharing a partial pathway 
with opioids, Song et al. (2013) has shown that P-SCS results in DH antinociception through 
activation of RVM OFF cells and 5-HT like cells, but has no effect on ON cells (Fig. 5) 
(Song et al., 2013a). Moreover, P-SCS mediated analgesia was attenuated with GABA 
receptor agonism but independent of opioidergic mechanisms within the RVM (Song et al., 
2013a). Because opioids and P-SCS share a partially redundant mechanism, opioidergic 
mechanisms may not contribute to P-SCS mediated analgesia, discussed in the ‘Endogenous 
Opioids’ section.
The descending noradrenergic pathway modulates ascending pain signals through the release 
of norepinephrine (NE) in the DH, specifically laminae I-III of the SG. Axons from the 
locus coeruleus (LC) and associated cell bodies provide descending spinal NE, synapsing on 
nociceptive afferents and lamina II spinal interneurons (Kwiat & Basbaum, 1992). While the 
LC, A5 and A7 all receive inputs from the PAG, the LC receives additional notable cortical 
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and sub-cortical relays (Bajic & Proudfit, 1999; Bernard et al., 1996; Cedarbaum & 
Aghajanian, 1978). Ascending signals originating in the DH send projections to the LC 
while redundant pathways relay from the insular cortices, amygdala and hypothalamus. This 
creates a neural circuit responsive to emotion and stress (Bernard et al., 1996; Gauriau & 
Bernard, 2002). It is likely that part of the analgesic effect from activation of the PAG is due 
to recruitment of the noradrenergic DAS (Cui et al., 1999; Bajic & Proudfit, 1999). Evidence 
for SCS modulation of the noradrenergic and serotonergic DAS is discussed below.
Segmental and Supraspinal neurotransmitters
Preclinical pain models have served to clarify mechanisms contributing to SCS-mediated 
analgesia. From careful lesioning experiments to direct DH sampling using microdialysis 
catheters, changes in neurotransmitter content, concentration and synthetic enzyme function 
have molded our understanding of these pathways. However, differences in implementation, 
methodology and inability to isolate cell-specific contributions to neurotransmitter release 
makes it critical to constantly reassess our understanding of spinal and supraspinal pain 
mechanisms. Specifically, it is unclear the extent to which an observed neurotransmitter 
change can be ascribed to a particular mechanism, as the pathways remain incompletely 
elucidated. For example, the relative contributions of interneurons, glia, non-nociceptive 
fibers and DAS to GABA release in response to SCS remains unclear. While we recognize 
the limitations of experimental models, progress has been made with regard to clarifying 
these pathways. We therefore discuss current constructs of pain signaling in SCS as they 
relate to the specific neurotransmitter, site of action and proposed origin.
Serotonin
Modulated by SCS and released in the DH, serotonin (5-hydroxytrypamine, 5-HT) is a 
monoamine neurotransmitter involved in the in the serotonergic DAS. A component of the 
RVM and a known serotonergic center, electrical stimulation of the nucleus raphe magnus 
led to GABA release in the DH, indicating that spinal 5-HT acts through a GABAergic 
intermediary (Kato et al., 2006; Tazawa et al., 2015). Interestingly, electrical stimulation of 
the PAG attenuated nociceptive inputs through a serotonergic mechanism, supporting that 
opioidergic mechanisms of analgesia also utilize this 5-HT DAS (Akil & Liebeskind, 1975; 
Liu et al., 1988). Preclinical pain models consistently demonstrate that descending 5-HT 
originates from the RVM and P-SCS models confirm this relationship (Vera-Portocarrero et 
al., 2006; Suzuki et al., 2004; Pertovaara, 2000; Newton & Hamill, 1988). While Peng et al. 
(1996) showed that analgesia from PAG stimulation was blocked by 5-HT3 receptor 
antagonists, Li et al. (2014) demonstrated that DH 5-HT resulting from P-SCS was 
exclusively synthesized in supraspinal nuclei and transported anterograde to nerve terminals 
(Peng et al., 1996; Li et al., 2014). Localizing the source of supraspinal 5-HT, Maeda et al. 
(2009) showed that P-SCS induced expression of c-Fos in the RVM (Maeda et al., 2009). 
Tazawa et al. (2015) further showed that the supraspinal nuclei and not the local spinal cord 
were responsible for production of 5-HT after P-SCS therapy. Moreover, they noted 
increased activation and number of serotonergic neurons in the dorsal raphe nucleus, a center 
adjacent to the ventral PAG with communications to the RVM and LC (Tazawa et al., 2015). 
Lastly, they noted that while both the serotonergic and noradrenergic DAS contributed to P-
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SCS-mediated analgesia, the 5-HT pathway played a greater role in antinociception (Tazawa 
et al., 2015). Together, these studies demonstrate activation of the serotonergic DAS in 
response to P-SCS therapy, which in turn innervates the DH, providing antinociceptive drive. 
Linderoth et al. (1992) first showed that DC stimulation increased 5-HT levels in the DH 
(Table 1) (Linderoth et al., 1992). Clarifying this observation, their group further 
demonstrated the presence of 5-HT staining nerve terminals in the SG and noted that 
intrathecal 5-HT potentiated the antinociceptive effects of P-SCS. Moreover, by showing 
that antinociception from P-SCS was attenuated with GABAB receptor antagonism and 
unchanged with muscarinic 4 acetylcholine receptor (M4 mAChR) antagonism, they 
demonstrated the presence of a GABAergic link and accelerated interest into 5-HT receptor 
subtyping (Table 2) (Song et al., 2009). Through agonist-antagonist studies, Song et al. 
(2011) utilized a rat model of mononeuropathy to clarify the role of 5-HT and GABA 
receptor subtypes on analgesia from P-SCS therapy (Song et al., 2011). Specifically, they 
noted that agonists of 5-HT2 and 5-HT3 receptors enhanced P-SCS analgesia while the 
benefits from 5-HT3 receptor agonists were inhibited more with antagonism of GABAB than 
GABAA receptors. While they did not discover any difference with 5-HTl, 5-HT6 and 5-HT7 
receptor antagonism, they noted that antagonism of 5-HT2A and 5-HT4 receptors attenuated 
the P-SCS response to tactile hypersensitivity. In total, their work suggests that while 5-
HT2A and 5-HT4 receptor agonism contributes to analgesia, P-SCS works to a greater extent 
through 5-HT3 receptors with a GABAB receptor link (Song et al., 2011). The preclinical 
evidence for neurotransmitter receptor subtype contribution to SCS-mediated analgesia is 
summarized in Table 2. These preclinical models indeed demonstrate that P-SCS activates 
the serotonergic DAS in an orthodromic manner (Fig. 5). However, the clinical magnitude of 
5-HT contribution to SCS-mediated antinociception is still unknown. Nonetheless emerging 
reports support the construct that serotonergic mechanisms play a significant role in pain 
relief. Prabhala et al. (2019), demonstrated that Duloxetine, a 5-HT and NE reuptake 
inhibitor, combined with P-SCS therapy significantly improved pain scores at one year 
compared to SCS alone (Prabhala et al., 2019). Taken together, preclinical and emerging 
clinical investigations suggest the significance of P-SCS mediated orthodromic activation of 
the serotonergic DAS for analgesia. However, further work is needed to determine if 5-HT 
may play a role in other paradigms, such as PF-SCS or DRG-S (Tables 1 and 2).
Gamma-aminobutyric acid
The principle inhibitory neurotransmitter of the CNS, GABA binds to two known GABA 
receptor classes: GABAA and GABAB (Olsen & DeLorey, 1999). The postsynaptic GABAA 
receptor complex consists of a multi-target binding domain linked with a chloride ionophore 
(Olsen & DeLorey, 1999). GABAA receptor agonism increases inward Cl− current, leading 
to postsynaptic hyperpolarization and increases the firing threshold (Olsen & DeLorey, 
1999). The metabotropic postsynaptic GABAB receptor indirectly opens potassium channels 
though a G-protein-coupled mechanism, leading to membrane hyperpolarization and a 
similar increase in firing threshold (Olsen & DeLorey, 1999). Uniquely, presynaptic GABAB 
receptors inhibit neurotransmitter release via a Ca2+ dependent mechanism and are critical in 
presynaptic inhibition (Todd, 2010; Olsen & DeLorey, 1999). Receiving projections from 
Aβ, Aδ and C fibers, GABAergic interneurons populate laminae I-III and demonstrate 
GABA positive terminals synapsing on PN (Todd, 2010; Zhang et al., 2014; Sivilotti & 
Caylor et al. Page 12
Bioelectron Med. Author manuscript; available in PMC 2019 August 21.
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
Woolf, 1994; Lekan & Carlton, 1995). Of all DH neurons, GABAergic signaling is present 
in 25% of lamina I, 30% of lamina II and 40% of lamina III (Todd, 2010). Dysfunction of 
the spinal GABA circuitry in addition to increased excitatory neurotransmitter release is 
correlated with WDR neuron hyperexcitability (Fig. 4) (Cui et al., 1997; Stiller et al., 1996). 
Yakhnitsa et al. (1999) demonstrated P-SCS decreases WDR neuron hyperexcitability, noted 
by depressed evoked potentials and decreased spontaneous discharge on these neurons 
(Yakhnitsa et al., 1999). This P-SCS-induced suppression of WDR neurons is thought to be 
due to an increase in DH GABA and concurrent decrease in excitatory glutamate (Cui et al., 
1997). SCS modulation of GABA in the DH and other CNS locations is a well-defined 
phenomenon (Table 1). Contributing mechanisms of analgesia utilizing specific GABAA and 
GABAB receptor pathways have been clarified using agonist-antagonist experiments (Table 
2). Converging lines of evidence confirm that P-SCS employs a GABAergic mechanism in 
the DH, as evidenced by inhibition of PN firing in response to P-SCS treatment (Sivilotti & 
Woolf, 1994; Duggan & Foong, 1985). Specifically, administration of a GABAA receptor 
antagonist reversed PN inhibition produced by P-SCS, demonstrating the importance of DH 
GABA to P-SCS mediated antinociception (Sivilotti & Woolf, 1994; Duggan & Foong, 
1985). Notably, P-SCS responders in an allodynic rat model were observed to have increased 
levels of GABA in the dorsal horn, whereas non-responders and sham animals exhibited no 
change, indicating that P-SCS mediated DH GABA release may prevent allodynia (Stiller et 
al., 1996). At the segmental level, suppression of glutamate release is dependent on 
presynaptic activation of GABAB receptors, which is likely more important to the P-SCS 
interneuron-mediated inhibition of PN firing than activation of postsynaptic GABAA 
receptors (Cui et al., 1997; Stiller et al., 1996; Cui et al., 1996). Expanding on these findings, 
Cui et al. (1997) found that administration of an intrathecal GABAB receptor agonist would 
transform P-SCS non-responding animals into responders (Cui et al., 1997). This finding is 
similar to the work by Song et al. (2011) that shows greater analgesia with 5-HT3 receptor-
mediated GABAB signaling than GABAA signaling (Song et al., 2011). It remains unclear 
which GABA-mediated effects are due to local interneuron circuitry and which are the result 
of activation of the serotonergic DAS. As noted previously, P-SCS recruits the serotonergic 
DAS, which employs downstream GABAergic mechanisms of antinociception. Using P-SCS 
and implanted microdialysis catheters, Stiller et al. (1995, 1996) and Linderoth et al. (1993) 
demonstrated an increase in extracellular GABA in the DH and decreased levels in the PAG 
(Stiller et al., 1996; Linderoth et al., 1993; Stiller et al., 1995). This decrease in PAG GABA 
argues that P-SCS relieves inhibition of the serotonergic DAS, which relays through the 
RVM, allowing the system to exert descending control over DH PN.
In clinical studies, Lind et al. (2004, 2008) showed that administration of an intrathecal 
GABAB receptor agonist (Baclofen) significantly enhanced the analgesia of P-SCS and 
rescued non-responders, echoing results of pre-clinical animal models (Lind et al., 2008; 
Lind et al., 2004). Cortical and subcortical pain circuits may also be modulated by P-SCS 
utilizing a GABAergic mechanism. Moens et al. (2013) studied 20 FBSS patients who were 
treated with P-SCS and underwent functional magnetic resonance imaging (fMRI) 7–10 
days post-implantation (Moens et al., 2013). They discovered increased GABA and 
decreased glucose signals in the ipsilateral thalamus, potentially explained by orthodromic 
activation of the paleospinothalamic pathway. They hypothesized that projections from the 
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reticular formations to GABAergic nuclei in the thalamus, hypothalamus and limbic system 
may indicate an interference with the affective component of pain (Moens et al., 2013; 
Moens et al., 2012). This would represent an additional mechanism of P-SCS efficacy. In 
summary, P-SCS mediated GABAergic mechanisms have been described at three targets. 
First, P-SCS activates GABAergic inhibitory interneurons at the dorsal horn, either directly 
or by recruiting the serotonergic DAS. Second, P-SCS results in decreased GABAergic 
signaling in the PAG, which results in disinhibition and thus activation of the serotonergic 
DAS. Lastly, P-SCS orthodromically activates thalamic GABAergic neurons, which may 
modulate cortical processing and thalamocortical dysrhythmia. Converging lines of evidence 
derived from preclinical and emerging clinical work suggest a central role for GABAergic P-
SCS mediated analgesia. These GABAergic pathways likely contribute to the observed 
clinical analgesic effects of P-SCS at both the segmental and supraspinal levels. Clearly, 
more work is needed to clarify these pathways in emerging paradigms, including DRG-S 
and PF-SCS (Tables 1 and 2).
Norepinephrine
Norepinephrine (NE), often referred to as Noradrenaline, is a catecholamine 
neurotransmitter produced primarily in the LC and released in the spinal cord DH 
(Hayashida et al., 2008a). In neuropathic pain, not only is there an increase in DH NE 
release and adrenergic axon sprouting, but corroborative evidence suggests an inability to 
recruit the DAS may contribute to chronic pain states (Hayashida et al., 2008b; Witting et 
al., 2003). NE has antinociceptive effects through presynaptic inhibition of primary Aδ and 
C fibers, postsynaptic inhibition of WDR and NS neurons, and activation of inhibitory 
interneurons (Hayashida et al., 2007; Pertovaara, 2006). In a rat model, the activation of 
inhibitory interneurons by NE increases GABAergic and glycinergic postsynaptic currents as 
measured in the SG (Baba et al., 2000a; Baba et al., 2000b). While this supports the 
segmental role for NE-mediated analgesia in the DH, converging lines of evidence now 
suggest that local DH NE release is unlikely to be augmented by P-SCS (Tazawa et al., 
2015; Song et al., 2013b). Song et al. demonstrated that while the LC is activated in a 
neuropathic rat model treated with P-SCS, no change was observed in DH NE (Song et al., 
2013b). Tazawa et al. (2015) supported this conclusion and further clarified that no increase 
in DH NE was observed with P-SCS (Tazawa et al., 2015). However, scant clinical reports 
confirmed concentrations of NE increased in CSF sampled after P-SCS therapy. Two 
separate human studies to date show an immediate increase in CSF NE concentration pre-to-
post P-SCS (Levin & Hubschmann, 1980; Liu et al., 2008). However, while Levin et al. 
(1980) showed an immediate increase in CSF NE, concentrations returned to baseline after 5 
min, calling into question the durable role of the noradrenergic DAS in P-SCS. In total, the 
current literature suggests that rather than recruiting descending NE fibers, orthodromic 
activation of the LC by P-SCS likely relays through the PAG, in essence reinforcing 
descending antinociception through the serotonergic DAS previously discussed (Fig. 5). The 
clinical longevity and significance of potential increases in CSF NE mediated by P-SCS, PF-
SCS, and DRG-S remains to be determined.
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Acetylcholine
Though the mechanism is not clearly defined, cholinergic inputs to PN play a role in 
modulating nociceptive signals via spinal interneuron circuitry (Foreman, 2012). Clonidine, 
a presynaptic alpha 2 (α2) adrenergic receptor agonist, exerts its analgesic effect largely 
through a cholinergic mechanism at the spinal level (Foreman, 2012). After discovering that 
clonidine may potentiate the analgesic effect of P-SCS in a rat model, Schechtmann et al. 
(2008) demonstrated lower basal DH ACh in nerve-lesioned animals and an increase in DH 
ACh in P-SCS responding animals (Schechtmann et al., 2008). Using agonist-antagonist 
studies, their group further noted reversal of analgesia with administration of selective and 
non-selective muscarinic acetylcholine receptor (mAChR) antagonists (Table 2). 
Specifically, they noted that muscarinic 1 (M1) mAChR and M4 mAChR contributed to P-
SCS mediated analgesia while nicotinic and muscarinic 3 (M3) mAChrR antagonism had no 
effect on PWT. Supporting this finding and further clarifying the receptor subtypes involved, 
Song et al. (2008) found that intrathecal muscarinic 2 (M2) mAChR and M4 mAChR 
agonists reversed P-SCS non-responders (Song et al., 2008). However as noted above, Song 
et al. (2009) showed that 5-HT signaling in the serotonergic DAS did not involve the M4 
mAChR pathway (Song et al., 2009). Thus, cholinergic signaling in P-SCS may represent a 
novel, independent mechanism exclusive of the serotonergic DAS or a parallel, redundant 
pathway. In a subsequent randomized clinical trial, Schechtmann et al. (2010) delivered sub-
analgesic doses of intrathecal clonidine or baclofen combined with P-SCS in non-responding 
patients with prior P-SCS devices. Similar to the work by Lind et al. (2004, 2008) (Lind et 
al., 2008; Lind et al., 2004), Schechtmann et al. (2010) showed intrathecal clonidine 
significantly improved pain scores (in two patients) when combined with P-SCS. Together, 
this provides some clinical evidence for cholinergic augmentation in P-SCS non-responders 
(Schechtmann et al., 2010). In sum, cholinergic mechanisms play a role in P-SCS mediated 
segmental antinociception. However, as with other neurotransmitters, work is needed to 
clarify the clinical contribution of cholinergic mechanisms to the analgesic effects of newer 
paradigms, including PF-SCS and DRG-S.
Endogenous opioids
Endogenous peptides of the brain and spinal cord, β-endorphins, enkephalins and 
dynorphins are ligand classes that activate μ, κ and δ-opioid receptors. These ligands exert 
analgesia segmentally through direct receptor activation in addition to recruitment of the 
serotonergic and noradrenergic DAS (Benzon et al., 2014). A well-known opioidergic center, 
the PAG communicates with the DAS, medulla, dorsal raphe nucleus and the LC (Benzon et 
al., 2014). Causing hyperpolarization and signal inhibition through a G-protein coupled 
mechanism, μ, κ and δ-opioid receptors are widely present on pre and post-synaptic neurons 
of the DH (Benzon et al., 2014). As the μ-opioid receptor is known to play a role in the 
development of windup, modulation of the endogenous opioidergic system may potentially 
explain analgesia with SCS treatment (Guan et al., 2006). Providing a physiologic basis for 
this hypothesis, Wang et al. (2003) has shown that activation of the serotonergic DAS 
increases enkephalin and dynorphins in the DH (Wang et al., 2003). In line with this finding, 
Ding et al. (2008) showed that P-SCS resulted in an increase in thoracic DH dynorphin in a 
rat angina model (Ding et al., 2008). This suggests the possibility that κ opioid receptor 
activation may contribute to the analgesic effects of P-SCS (Ding et al., 2008). In a 
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subsequent SNI rat model, Sato et al. (2013) observed improved PWT after frequency-
specific P-SCS at 4 Hz and 60 Hz. Notably, they observed that the improvement with 4 Hz 
and 60 Hz was reversed upon administration of naloxone and naltrindole, respectively (Sato 
et al., 2013). Similar to what has been observed with transcutaneous electrical nerve 
stimulation (TENS), this finding indicates frequency-specific activation of μ and δ-opioid 
receptors with P-SCS (Sato et al., 2013; Chandran & Sluka, 2003). Despite frequency-
specific activation of opioidergic pathways, the role of this mechanism in P-SCS is likely 
temporally limited to the first few days of stimulation. In an SNI model treated with P-SCS 
at 3 and 7 days, naloxone administration attenuated early but not late reversal of 
hyperalgesia (Sun et al., 2017). Postulating that the temporal reduction in efficacy occurred 
through endogenous opioid tolerance, Chandran et al. (2002), observed similar findings in 
patients treated with both low and high frequency TENS (Chandran & Sluka, 2003). Limited 
evidence from clinical studies appears to mirror the results of these preclinical 
investigations. In 17 patients with chronic pain admitted to the neurosurgical service, Tonelli 
et al. (1988) implanted and initiated single lead P-SCS during hospital admission, sampling 
their CSF one to two days prior and again one day after implantation and initiation of 
therapy (Tonelli et al., 1988). Responders were noted to have a significant increase in CSF 
β-endorphin and β-lipotropin, a prohormone of the β-endorphin peptide. Unfortunately, CSF 
was not sampled at any additional timepoints to clarify whether this increase in β-endorphin 
was sustained (Tonelli et al., 1988). In other clinical work, Freeman et al. (1983) seemed to 
agree with preclinical models regarding the lack of sustained opioidergic mechanisms with 
P-SCS (Freeman et al., 1983). Specifically, naloxone did not reverse analgesia from P-SCS 
after 30 days of stimulation in patients having relief with TENS or P-SCS. This continues to 
suggest that recruited opioidergic mechanisms may contribute to the initial analgesic 
efficacy of P-SCS (during P-SCS trial and subsequent implant) but the longevity of this 
mechanism is questionable. There is likely an analgesic ceiling effect in regard to 
opioidergic pathways recruited by P-SCS. In a rat SNI model treated with P-SCS, 
administration of the opioidergic enhancer proglumide had no additive or synergistic effect 
on PWT or physical activity levels (Inoue et al., 2017). Tolerance and time-limited 
opioidergic analgesia that contribute to the clinical efficacy of P-SCS may also apply to PF-
SCS. To date, one study of non-lesioned rat lumbar spinal cord slices demonstrated 
frequency-dependent opioid release from DH neurons, with a maximal release at 500 Hz 
(Song & Marvizón, 2003). Further work is needed to determine the role and longevity of 
opioidergic mechanisms in all modes of SCS. Moreover, additional studies are needed to 
evaluate frequency-specific endogenous opioid release in P-SCS and PF-SCS and whether 
these mechanisms are predominantly segmental or supraspinal.
SCS modulates Neuroinflammatory pain regulation
Signatures of glial activation
Critical to the structure, metabolism and immunity of both the CNS and peripheral nervous 
system (PNS), glia are non-neuronal cells intimately associated with neurons. Glia of the 
CNS include microglia, astrocytes, oligodendrocytes and ependymal cells while those of the 
PNS include satellite glial cells (SGCs) and Schwann cells (Ji et al., 2013). It is now 
understood that glia also provide a functional microenvironment modulating signal 
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transduction, neuroplasticity and synaptic pruning (Tremblay et al., 2011). In response to 
nerve injury, striking changes are seen in glial morphology, concentration, cellular signaling, 
receptor regulation and mediator release. Termed gliosis, these responses together constitute 
a phenotypic transformation that alters signaling by changing the synaptic neuron-glia 
mediator balance (Fig. 6) (Ji et al., 2013). Temporally correlating with the onset of 
neuropathic pain, PNS and CNS insults including nerve injury and cord hypoxemia lead to 
reactive gliosis. Specifically, reactive gliosis leads to increased post-synaptic potentials at 
excitatory synapses and decreased post-synaptic potentials at inhibitory synapses (Fig. 6). 
Through complex signaling mechanisms, these changes result in increased PN firing and 
pathologic nociception (Ji et al., 2013). While microglial activation occurs 24 h after injury 
and is limited to 3 months, astrocyte activation occurs 3 days after injury and is maintained 
(Coyle, 1998; Ledeboer et al., 2005; Mika, 2008; Mika et al., 2009). Activation and 
intracellular signaling culminate with the release of glial mediators, which exhibit their 
downstream effect on pre and post-synaptic targets (Fig. 6) (Ji et al., 2013; Mika et al., 
2013). Mediator classes known to influence nociceptive transmission include nitric oxide 
(NO), cytokines, chemokines, complement components and other bioactive factors, some of 
which have been examined in response to SCS (Table 3) (Mika et al., 2013). Given that glial 
activation is important to the development and maintenance of neuropathic pain and that 
glial inhibition improves mechanical allodynia, one potential mechanism of SCS is glial 
modulation (Watkins et al., 2001a; Watkins et al., 2001b). In a seminal pre-clinical study, 
Sato et al. (2014) showed decreased glial activation after P-SCS therapy correlating with 
improved PWT (Sato et al., 2014). Specifically, P-SCS decreased immunostaining of 
microglia marker OX-42 and astrocyte markers GFAP and MCP-1 in the superficial and 
deep DH lamina (Sato et al., 2014). Changes in glial activation are also observed at the 
DRG.
DRG SGCs are perfectly positioned within the sandwich synapse to regulate nociceptive 
transmission (Todd, 2010; Rozanski et al., 2013). Encircling a single neuron with a thin 
sheath intrasynaptically, SGCs are implicated in nociceptive modulation (Hanani, 2005). 
Having multiple bioactive receptors, SGC modulate neural activity through the release of 
mediators that have been shown to alter neural activity via the P2X3 pathway. The 
upregulation of this pathway promotes abnormal nociception in rats (Hanani, 2005; Chen et 
al., 2008). In a L5 SNI model, SGC activation was observed while glial inhibitors 
administered to the ipsilateral DRG provided alleviation of mechanical allodynia (Liu et al., 
2012a). Moreover, SGC reorganization and the formation of new neural contacts and gap 
junctions has been observed after peripheral nerve axotomy (Hanani et al., 2002). Given the 
proximity to the DRG, DRG-S may modulate SGC activation. In a tibial nerve injury model, 
Pan et al. (2016) first showed that DRG-S normalized glial fibrillary acidic protein (GFAP) 
and activating transcription factor 3 (ATF-3), markers of astrocytic activation and neuronal 
injury (Pan et al., 2016). Moreover DRG-S was noted to reverse cold and mechanical 
hypersensitivity, suggesting that DRG-S impacts SGC-mediated neuroinflammation (Pan et 
al., 2016). While evidence is still limited, SGCs clearly play a role in the development of 
pain states, modulation of which may explain the efficacy of DRG-S. It is unknown if other 
SCS paradigms modulate SGC activity or are efficacious at the DRG. To date, no human 
clinical work has yet been completed that characterizes these promising observations seen in 
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DRG-S treated preclinical models. Taken together, neuroinflammatory glial mechanisms are 
critical in chronic pain maintenance while glial-mediated mechanisms of P-SCS, PF-SCS 
and DRG-S remain to be elucidated. While a comprehensive examination of glial activation 
is beyond the scope of this review, the evidence for glial mediator response to modes of SCS 
are carefully summarized in Table 3 and reviewed below.
Cytokines, neurotrophic factors and biomarkers
Critical to the induction and maintenance of chronic pain, dysregulation of local cytokine 
and neurotrophic factor signaling directly and indirectly influences AP generation in the PN. 
The release of inflammatory cytokines, neurotrophic factors and other mediators operates 
under a positive feedback mechanism of autocrine and paracrine regulation. While likely 
evolutionarily advantageous in recruiting the inflammatory cascade, gliosis and the resultant 
local inflammatory response becomes a maladaptive and injurious process in chronic pain. 
While evidence for glial modulation in response to SCS is mounting, the effect of SCS on 
the local and systemic inflammatory responses remains unclear.
Upregulated in gliosis after nerve injury, the proinflammatory cytokines interleukin-1β 
(IL-1β), IL-6, IL-8 and TNF-α exert potent pronociceptive action (Bjurstrom et al., 2016). 
Of particular importance, IL-1β and TNF-α increase PN excitability, reinforce glial 
activation and further recruit the inflammatory response (Bjurstrom et al., 2016). 
Concentrations of CSF proinflammatory cytokines are increased in multiple chronic pain 
states including osteoarthritis, CRPS, postherpetic neuralgia and fibromyalgia (Bjurstrom et 
al., 2016). Patients with indications for SCS therapy including chronic low back pain, 
lumbar radiculopathy and failed back surgery syndrome (FBSS) were also noted to have 
elevations in proinflammatory cytokines (Bjurstrom et al., 2016). Post P-SCS effects in pre-
clinical models have been evaluated with regard to cytokine levels, summarized in Table 3. 
In non-nerve injury models treated with P-SCS, Tilley et al. (2009) demonstrated increased 
expression of meningeal TNF-α and IL-10, but no change was noted in IL-6 or IL-1β 
(Tilley et al., 2009). Later, Tilley et al. carefully separated the meninges into its three layers 
and measured cytokine expression following P-SCS (Tilley et al., 2019). They found 
increases in IL-1β and IL-10 within the dura mater, correlated in a dose-dependent manner 
to the delivered current (Tilley et al., 2019). Further, the concentration of IL-6, a pleiotropic 
cytokine, was notably related to delivered current with a bell-shaped relationship (Tilley et 
al., 2019). Together, these studies demonstrate a possible relationship between cytokine 
expression and delivered current. In a SNI rat model treated with P-SCS, Tilley et al. (2017) 
demonstrated decreased DRG expression of IL-6, which is normally upregulated in 
neuropathic pain models (Tilley et al., 2017; Ha et al., 2001) and they also noted increased 
expression of the IL-1β (Tilley et al., 2017). Evaluation of clinical cytokine profiles in SCS 
therapy may not only elucidate a potential mechanism, but also serve to guide clinical 
therapy and response. Measuring interstitial fluid sampled from artificial skin blisters, Kriek 
et al. (2017) investigated the immunomodulatory effects of P-SCS on CRPS (Kriek et al., 
2018). They showed significant reduction in interferon-γ-inducible protein 10 and vascular 
endothelial growth factor (VEGF). However, they ascertained no significant change in the 
proinflammatory cytokines IL-2, IL-6, IL-12, IL-15, IL-17, IFN-γ, or TNF-α or the anti-
inflammatory cytokines IL-4, IL-5, IL-10 or IL-13 (Table 3) (Kriek et al., 2018). In clinical 
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work by Kinfe et al. (2017) evaluating the effects of B-SCS, peripheral blood concentrations 
of the anti-inflammatory cytokine IL-10 interestingly increased in responders, however, 
changes in levels of other cytokines were not determined to be statistically significant (Kinfe 
et al., 2017). This finding has to be carefully considered, as other variables including 
reduced pain levels, changes in mood or improvement in sleep could also explain the 
finding. The plausibility that an electrical pulse applied to the thoracic spinal cord could 
directly modulate systemic cytokine levels is difficult to rationalize. As there are no 
published clinical studies evaluating CSF cytokine levels after treatment with P-SCS, further 
work is clearly needed to determine if cytokine modulation is a contributing mechanism to 
analgesia.
Nerve Growth Factor (NGF), Brain Derived Neurotrophic Factor (BDNF) and Glial Cell 
Line-Derived Neurotrophic Factor (GDNF) are essential neurotrophic factors for 
maintenance and regeneration after PNS or CNS injury. Known to activate and sensitize 
nociceptive neurons, inflammation triggers NGF expression in mast cells, macrophages, and 
Schwann cells (Pezet & McMahon, 2006). CSF neurotrophic factor concentrations are 
increased in patients with chronic lower back pain, lumbar radiculopathy and failed back 
surgery syndrome, all known targets of SCS therapy (Pezet & McMahon, 2006). Similarly, 
increased BDNF expression is observed in DRG neurons, microglia, and astrocytes in 
inflammatory and neuropathic pain models (Ha et al., 2001; Pezet & McMahon, 2006; 
Vanelderen et al., 2010; Biggs et al., 2010). GDNF, expressed in astrocytes, peripheral 
tissues and active chondrocytes, is thought to contribute to neuroinflammatory mediated pain 
(Bjurstrom et al., 2016; Pezet & McMahon, 2006). In 2017, Tilley and colleagues showed 
increased expression of BDNF after SNI, though no change was seen with application of P-
SCS (Tilley et al., 2017). In two separate studies of FBSS patients being treated with P-SCS 
by McCarthy et al. (2013, 2014), CSF concentrations of the neurotrophic factors BDNF and 
GDNF were observed to be high in P-SCS treated patients compared to healthy controls 
(McCarthy et al., 2013; McCarthy & McCrory, 2014b). However, they did not observe any 
effects of P-SCS therapy on BDNF and GDNF levels. Other mediators play a role in 
nociception and provide a possible contributing mechanism to the efficacy of SCS. In FBSS 
patients treated with P-SCS, McCarthy et al. (2013) described elevated CSF concentration of 
the inflammatory chemokine monocyte chemoattractant protein 1 (MCP-1) (McCarthy et al., 
2013). This remains the only published report of an elevated chemokine with P-SCS 
treatment. Significant changes have also been observed in neuroimmune and nociceptive 
signaling proteins after treatment with P-SCS, measured in the CSF by proteomic mass 
spectrometry (Lind et al., 2016). Lastly, one study evaluated the CSF concentrations of non-
ionized periodic elements in patients with implanted P-SCS devices (Korvela et al., 2016). 
While no change was noted in any element before or after P-SCS therapy, significantly 
higher concentrations of several elements were noted in patients with chronic pain compared 
to healthy controls (Korvela et al., 2016). However, it is difficult to interpret the lack of 
change with P-SCS therapy as these patients potentially had an inadequate washout period.
Although there is a paucity of clinical work, some preclinical studies support the effect of P-
SCS on biomarkers of chronic pain. Collectively, there is evidence that P-SCS modulates 
neuroinflammation and nociception (Table 3). Variability in the published literature and gaps 
in knowledge currently prevent the clinician from identifying the response of 
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neuroinflammation to SCS. While Table 3 summarizes the available preclinical and clinical 
data, it is difficult to make definitive statements regarding the response of cytokines and 
other mediators to SCS therapy. Although the current literature is sparse and divided, pre-
clinical work is underway that may clarify the response of these complex inflammatory 
signaling cascades to multiple modes of SCS (Tilley et al., 2019). As such, there is a clear 
need for this pre-clinical work to translate to clinical studies that carefully measure 
immunomodulatory profiles, both centrally and peripherally.
Sexual dimorphism, inflammation and potential mechanisms in SCS
Evidence has emerged for the existence of sex-specific differences in chronic pain pathways 
(Fillingim et al., 2009). In addition to a higher incidence of neuropathic pain, 
musculoskeletal pain, fibromyalgia, low back pain and migraine, women are also noted to 
exhibit increased sensitivity and decreased tolerance to applied experimental pain stimuli 
(Fillingim et al., 2009). Though the etiology of these differences is likely multifactorial, 
investigative efforts have begun to unveil sex-specific mechanisms of hyperalgesia and 
allodynia in preclinical models. While it is unknown if there is a sex-based discrepancy in 
response to SCS, there exists a potential for sex-specific SCS device programming or 
pharmacotherapeutic adjuvants to augment clinical benefit. Thus, further elucidation of these 
pathways may translate to the clinical use of targeted therapies for both male and female 
patients.
In order to limit experimental variability, the majority of animal models used to construct the 
foundations of preclinical pain research have been male. Sorge et al. (2011) first identified a 
male-specific, testosterone-dependent pathway involving spinal toll-like receptor 4 (TLR4), 
a receptor primarily present on spinal microglia (Sorge et al., 2011). Their work suggested 
that a TLR4-independent pathway was responsible for allodynia in females. Interestingly, 
the administration of testosterone to female mice acted as a ‘switch’, activating the male-
specific pathway (Sorge et al., 2011). In their seminal work published in 2015, Sorge and 
Mogil further characterized this observed sexual dimorphism, noting both conserved and 
unique pathways to hypersensitivity and allodynia (Sorge et al., 2015). Specifically, while 
intrathecal NMDA antagonism reversed mechanical hypersensitivity regardless of gender, 
they noted a male-specific microglial upregulation of the P2X4 receptor (P2X4R), crucial to 
the development of allodynia via the MAPK-dependent synthesis of BDNF. Their group 
further used dorsal horn gene expression and tamoxifen-dependent microglial BDNF-
knockouts to demonstrate that while mechanical hypersensitivity in males is dependent on 
microglia, the female correlate relies on a mechanism of adaptive immunity, likely 
dependent on T-cells (Sorge et al., 2015). With suppression of the adaptive immunity 
pathway, females revert to the male-specific, microglia-dependent pathway (Sorge et al., 
2015). Confirming this observation in another species, their group used SNI and CCI rat 
models to identify microglia and P2X4R as key points of divergence between the sexes. 
Moreover, they noted that while intrathecal administration of male P2X4R-stimulated 
microglia caused allodynia in both male and female naïve rats, injecting female P2X4R-
stimulated microglia had no effect on animals of either sex (Mapplebeck et al., 2018). In 
evaluating the increased expression of P2X4R, the investigators evaluated IRF5, a 
transcription factor known to regulate P2X4R gene expression. Interestingly, despite 
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elevated spinal levels in both male and female nerve injury models, IRF5 was noted to 
exclusively bind to the P2X4R gene promoter region in male rats, but not females 
(Mapplebeck et al., 2018). Together, evidence from these preclinical models suggests that 
the development of mechanical hypersensitivity may rely on an innate and adaptive immune 
process in males and females, respectively. If proven in human studies, these sex differences 
may lead to a poor clinical response to microglial inhibitors in females and account for the 
current reported lack of efficacy in clinical trials that include both genders (Brings & Zylka, 
2015). In line, SCS mechanism that may act through TLR4, P2X4R, or IRF5 pathways may 
be differentially regulated in male and female patients.
With an increased incidence of chronic pain and autoimmune disease amongst women, it is 
conceivable that adaptive immunity and T cells link the pathophysiology of these seemingly 
separate processes. Known to induce allodynia through a T cell mediated mechanism and 
normally hidden from immune surveillance, a conserved region of myelin basic protein 
(MBP) is a degradation product of the protective sheath enwrapping Aβ Fibers (Liu et al., 
2012b). After demonstrating that the injection of MBP 84–104 fragment into naïve nerves 
induced an ipsilateral inflammatory and immune cascade, Liu et al. (2012) postulated that 
nerve injury and repeated exposure of this hidden region on MBP led to a deleterious, 
allodynia-reinforcing immune reaction (Liu et al., 2012b). Expanding on this, Chernov et al. 
(2018) interestingly demonstrated that sciatic nerve injection of the MBP 84–104 fragment 
induced long-lasting mechanical allodynia in female, but not male animals (Chernov et al., 
2018). Moreover, they also observed sexual dimorphism in gene expression profiles 
measured in the sciatic nerve, DRG and spinal cord post injection. Additional work by the 
same group further supports an autoimmune mechanism in females, demonstrating sero-
positivity for autoantibodies to the MBP 84–104 fragment (Hullugundi et al., 2017). A 
proinflammatory protease responsible for the cleavage of MBP to its immunogenic products, 
matrix metalloproteinase 9 (MMP-9) contributes to acute and late phase peripheral 
neuropathy (Liu et al., 2012b; Remacle et al., 2018). Interestingly, however MMP-9 activity 
and disinhibition were comparably elevated in both male and female CCI models (Remacle 
et al., 2018). Along with their previous work, this argues that the sex-specific pathways 
diverge at the immune response to MBP. To date there is only one clinical translational P-
SCS study that examined MMP-9 response pre-to-post P-SCS, finding no difference in 
MMP-9 or its inhibitor, though it did not evaluate for differences by gender (Kamieniak et 
al., 2019b). While sexual dimorphism likely plays a role in the innate and adaptive immune-
mediated development of allodynia, it remains unclear if SCS is capable of achieving 
antinociception via modulation of these pathways.
Sex-specific differences have also been observed in opioid responsiveness and signaling, 
though this remains disputed (Mogil, 2012). Preclinical research implicates differential 
activation of microglia and TLR4 at the supraspinal level as responsible for the observed 
sex-dependent opioid response. In an animal model, Doyle et al. (2017) demonstrated that 
activation of female microglia in the PAG reduced typical antinociceptive pathways through 
the TLR4 specific pathway (Doyle et al., 2017). Notably, intra-PAG injection of naloxone, 
blocking morphine’s interaction with TLR4, increased female analgesia to the level of their 
male counterparts. As supraspinal mechanisms of SCS intricately engage the PAG and DAS, 
there is a clear need to further our understanding of the interaction between SCS and sex-
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specific opioidergic antinociception. Current clinical studies of SCS are predominantly 
carried out in both genders without sex comparisons. In one recent CSF-sampled proteomic 
study of 11 female and 3 male patients with P-SCS, Lind et al. (2016) demonstrated that the 
greatest changes occurred in neuroprotection, synaptic plasticity, nociceptive signaling and 
immune regulation (Lind et al., 2016). While this predominantly female study did not assess 
for sexual dimorphism, advanced techniques including protein and gene profiling are 
capable of identifying the interaction between sex, neuro-immunity and inflammation (Ray 
et al., 2019). To our knowledge, no preclinical or clinical studies have evaluated the sex-
specific response to P-SCS, PF-SCS, DRG-S or ECAP-SCS. Given the emerging 
understanding of these sexually dimorphic pathways, investigation is warranted to determine 
if SCS therapies alone or in combination with pharmacotherapy have a differential effect on 
male or female patients.
Quantitative sensory testing
Utilized both as a clinical and basic science tool, quantitative sensory testing (QST) 
evaluates the small and large fibers, which detect changes in temperature as well as vibration 
and electrical stimulation, respectively (Shealy et al., 1970). Categorically, undergoing QST 
yields sensory data with regard to a particular stimulus. This includes the threshold, which is 
the minimum sensory input for the subject to experience the onset of change. Modern QST 
evaluates thermal, mechanical vibratory and electrical paresthesia thresholds. QST also 
assesses for tolerance, the point at which the stimulus causes unbearable discomfort. Heat, 
cold, mechanical and electrical tolerances can be measured by QST. As it evaluates the 
function of the small and large fibers, QST has contributed to both the elucidation of P-SCS 
MOA as well as has become a predictive tool for its efficacy. Pioneering the effect of P-SCS 
on QST, Shealy et al. (1970) first demonstrated an increase in deep muscle pain threshold 
(Shealy et al., 1970) while Lindblom et al. (1975) reported increased tactile and vibratory 
thresholds but no change in pinch pressure threshold (Lindblom & Meyerson, 1975). 
Interestingly, a subsequent group found that electrical thresholds were only increased within 
the area of paresthesia produced by P-SCS (Doerr et al., 1978). More recently, Mironer et al. 
(2000) found that P-SCS also increased electrical tolerance, which interestingly correlated 
with P-SCS mediated pain reduction (Mironer & Somerville, 2000). While diverging 
evidence from Alo et al. (1999) did not replicate the findings of increased electrical 
tolerance or correlation with pain reduction from P-SCS, they interestingly noted that P-SCS 
decreased electrical threshold bilaterally irrespective of pain laterality (Aló & Chado, 2000). 
While warmth threshold, heat pain threshold and heat pain tolerance were increased in two 
QST studies post P-SCS, Marchand et al. (1991) further noted no change in visual light 
threshold or tolerance, arguing against a global mechanism for P-SCS-mediated analgesia 
and rather for a targeted segmental or supraspinal mechanism (Marchand et al., 1991; 
Ahmed et al., 2015). Though smaller and older studies seems to demonstrate a clear effect of 
P-SCS on QST metrics (Münster et al., 2012; Rasche et al., 2006; Burkey & Abla-Yao, 
2010; Cata et al., 2004), newer diverging lines of evidence demonstrate lackluster results 
(Meier et al., 2015; Biurrun Manresa et al., 2015), including the largest controlled study to 
date (Kemler et al., 2001). While the etiology of the discrepancy remains to be elucidated, a 
review of published literature is altogether temporally summarized in Table 4. Very limited 
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evidence exists for the effect of novel SCS paradigms on QST metrics. To date the only 
clinical QST study comparing HF-SCS to P-SCS, Youn et al. (2015) demonstrated that HF-
SCS alters mechanical thresholds to a greater extent than either P-SCS or sham. In line with 
preclinical models, this offers a novel HF-SCS MOA, possibly explained by the differential 
recruitment of larger fibers (Youn et al., 2015). In as much, QST has the potential to 
elucidate novel PF-SCS MOA. Dynamic QST has recently emerged as a potential method of 
clarifying SCS MOA as it evaluates temporal summation (TS) and conditioned pain 
modulation (CPM). TS, a phenomenon whereby repeated stimuli result in increased pain, is 
associated with central sensitization (Vierck Jr et al., 1997). Thought to gauge DAS function 
and correspondent to diffuse noxious inhibitory control (DNIC), CPM is a phenomenon 
whereby a second noxious stimulus applied elsewhere decreases pain perception from the 
initial pain location (Le et al., 1992; Le Bars et al., 1979). Interestingly, while Campbell et 
al. (2015) were unable to demonstrate a change in QST thresholds to P-SCS, they found that 
patients who exhibited enhanced TS and reduced CPM at baseline reported decreased pain 
scores after three months of P-SCS (Campbell et al., 2015). Further supporting these 
findings, Eisenberg et al. (2015) demonstrated that P-SCS attenuates TS and leads to 
improved self-reported pain (Eisenberg et al., 2006; Eisenberg et al., 2015). Together, while 
multiple studies have demonstrated the utility of QST and dynamic QST as objective 
sensory markers, there still exists wide variability in clinical data. Though this variability is 
likely due to small sample size, differences in patient characteristics and methodological 
dissimilarities, QST and dynamic QST remain promising clinical tools that require further 
exploration. There is a clear need for larger, more rigorous, randomized controlled trials to 
determine if QST metrics improve candidate selection and guide device programming for P-
SCS, PF-SCS and DRG-S paradigms.
Neurophysiologic testing
The neurophysiological effects of P-SCS on the human spinal cord has been a crucial area of 
study in understanding the mechanistic properties of the therapy, as well as furthering its 
development (Sankarasubramanian et al., 2018a). The effect of P-SCS in cortical processing 
can be measured via somatosensory evoked potentials (SSEPs), or the activity in the cortex 
measured via EEG that results from peripheral electrical stimulation (Fig. 7). Using this 
paradigm, numerous studies have demonstrated that P-SCS can have an inhibitory effect on 
the amplitude of the SSEP in response to noxious stimuli, which in turn would modify the 
experience of the painful sensation (Wolter et al., 2013). Additional research has looked into 
the effect of P-SCS on the sensorimotor reflexes mediated by Aβ, Aδ, and C sensory 
afferents (Sankarasubramanian et al., 2018a; De Andrade et al., 2010). In a study of 20 
patients, the authors demonstrated that P-SCS attenuated the H-reflex, a monosynaptic arc in 
the spinal cord, such as the Achilles tendon reflex, as well as the RIII, a polysynaptic 
withdrawal reflex, such as withdrawing one’s hand from a hot surface. Furthermore, it was 
shown that in this treatment group, the attenuation of the RIII correlated with pain relief 
from the P-SCS. This finding was also supported by other studies (García-Larrea et al., 
1989; Manresa et al., 2015).
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SCS affects cortical and subcortical pain processing
Cortical and subcortical signatures of pain
Despite the advent of PET, fMRI, SPECT, MEG and high-density EEG, the neural 
representation of nociception and the experience of acute and chronic pain remains ill-
defined (Mouraux et al., 2011). Acute nociception is an alerting response. This alerting 
function engages salience networks that in the past were ascribed as part of the “Pain 
Matrix”. Recent work refute inclusion of these salience neural network nodes (that are 
equally engaged with alternative sensory modalities, i.e., a blaring auditory stimuli) when 
examining the salience of a pain percept (Mouraux et al., 2011). Nonetheless, chronic pain 
consistently activates areas such as the primary and secondary somatosensory cortex (SI, 
SII), thalamus and prefrontal cortex (PFC) as well as salience network nodes including the 
insular cortex (IC), dorsal Anterior Cingulate Cortex (dACC) (that may in part amplify the 
attention paid to chronic pain symptom, i.e., a perpetual “alerting” signal) (Apkarian et al., 
2005; Barad et al., 2009). Beside the salience network, the neural representation of 
nociception is described as the sensory-discriminative network (SDN) and the affective-
emotional network (AEN). The SDN is composed of the thalamus, SI, SII and posterior IC, 
with sensory discriminative pain relayed through the ventroposterior-lateral and 
ventroposterior-medial thalamic nuclei and is also termed the neospinothalamic pathway. 
The AEN is composed of the dACC (area 24), the rostral (dorsoposterior IC) and Anterior 
IC while affective sensory information to the AEN is thought to be relayed through the 
mediodorsal thalamus, also termed the paleospinothalamic pathway (Barad et al., 2009) 
(Fig. 8). Prior basic science and clinical work confirm the mediodorsal thalamus is important 
in the processing of emotion (Metzger et al., 2010), affective pain processing (pain un-
pleasantness) (Metzger et al., 2010; Brooks & Tracey, 2005; Ploner et al., 1999; Rainville et 
al., 1997; Vogt & Paxinos, 2014; Vogt et al., 1979), thought to occur through mediodorsal 
thalamic connections with dorsal ACC (area 24). In a demonstrative case study, a patient 
with an isolated somatosensory cortex stroke that spared the dorsal ACC (area a24) and 
thalamus (including mediodorsal thalamus) reported usual contralateral limb analgesia to 
painful stimuli, but the patient continued to report an “unpleasant” feeling with the 
application of painful stimulus, suggesting in vivo separation of the affective and sensory 
discriminative pain pathways (Ploner et al., 1999). Using machine learning and fMRI to 
evaluate thermal pain, social pain and remifentanil response, Wager et al. demonstrated > 
90% sensitivity and specificity in using neurological signatures that identified reproducible 
pain patterns in the thalamus, posterior and anterior IC, SI/SII, ACC and PAG (Wager et al., 
2013), providing an ample construct for the involvement of the IC and ACC in the pain 
experience. In support of this construct, a 2016 metanalysis of fMRI and PET neuroimaging 
demonstrated that the anterior IC, ACC and thalamus were highly conserved in pain 
processing, irrelevant of imaging modality measures or the pain source (i.e., body part) 
(Jensen et al., 2016). Moreover, a 2005 metanalysis discerned a difference between pain 
experience of acute and chronic pain: acute pain stimuli in healthy control subjects were 
consistent with activation of the SDN while the chronic pain patients exhibited greater 
activation of the prefrontal cortex, thought to reflect an increase in cognitive, emotional, and 
introspective components (critical to AEN) (Apkarian et al., 2005; Jensen et al., 2016). 
Although discrete regions may perform modality specific pain processing functions, there 
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remains wide overlap in neural activation between acute and chronic neuropathic and 
nociceptive pain (Barad et al., 2009). Chronic neuropathic pain, partially due to spinal 
pathophysiologic processes, is known to similarly result in pathological neurodegenerative 
process in cortical and subcortical structures. In 2004, Apkarian et al., showed that patients 
with chronic low back pain exhibited atrophy of the dorsolateral PFC and thalamus 
(Apkarian et al., 2004) demonstrative of chronic pain regional morphometric changes. 
Moreover, they showed that patients with neuropathic pain exhibited greater volume loss 
than those with non-neuropathic pain and that the duration of pain correlated with volume 
loss, indicating the presence of progressive degeneration over time (Apkarian et al., 2004). 
Further, chronic pain patients compared to controls demonstrate thalamic volumetric and 
morphometric changes as well as decreased activation in parts of the PFC, which may 
represent decreased activation of descending inhibition, or neuropathy dependent reduction 
in utilization due to diminution of afferent signaling (Jensen et al., 2009; Jensen et al., 2012; 
Segerdahl et al., 2015). Collectively pathological processes that contribute to chronic pain 
are pervasive throughout the neuraxis, (spinal cord and brain) that integrates sensory 
discriminative as well as emotional and affective pathways (Fig. 8).
Cortical and subcortical processing with SCS
Functional imaging techniques, such as positron emission tomography (PET), functional 
magnetic resonance imaging (fMRI) and Magnetoencephalography (MEG) have been used 
to investigate neural activation and/or attenuation pre-to-post P-SCS, (Moens et al., 2013; 
Moens et al., 2012; Schulman et al., 2005; Oluigbo et al., 2012; Nihashi et al., 2004; 
Kunitake et al., 2005; Pahapill & Zhang, 2014; Kishima et al., 2010; Stancák et al., 2008; 
Nagamachi et al., 2006; Sufianov et al., 2014; Elaine et al., 1997; Hosobuchi, 1985; 
Deogaonkar et al., 2016) while relatively recent work has begun to systematically compare 
the neural effects of P-SCS versus PF-SCS with fMRI and PET. Moens et al. (2018) showed 
that there are clear differences between P-SCS and PF-SCS. First, with a randomized block 
design, they employed paresthesia based low frequency (4 Hz, 60 Hz) and paresthesia based 
HF-SCS (500 Hz and 1 kHz) compared to sub-threshold or PF-SCS (4 Hz, 60 Hz, 500 Hz 
and 1 kHz). At all frequencies, PF-SCS resulted in greater cortical (frontal brain regions: 
limbic, sensory, and motor as well as diencephalon) activity than subthreshold (below 
paresthesia) PF-SCS/HF-SCS (De Groote et al., 2018). Interestingly, P-SCS resulted in 
greater deactivations in parahippocampus, amygdala, posterior cingulate gyrus (PCG), 
precuneus and superior temporal gyrus, when compared to decreases with subthreshold PF-
SCS/HF-SCS (De Groote et al., 2018). Moens et al. (2018), postu-lated that P-SCS 
deactivation of parahippocampus and PCG, both with reciprocal connections to default 
mode network (DMN) targets that include the dorsal thalamus and inferior parietal lobe 
(Buckner et al., 2008), could be clinically relevant, given that dysfunctional DMN con-
nectivity occurs in chronic lower back pain (Baliki et al., 2008; Letzen & Robinson, 2017), 
complex regional pain syndrome (Bolwerk et al., 2013), and failed back surgery syndrome 
(Letzen & Robinson, 2017; Kornelsen et al., 2013). In line with these results, Deogonaker et 
al. (2016) reported increased DMN connectivity with optimal P-SCS, further supporting that 
P-SCS may correct dysfunctional DMN connectivity associated with chronic pain 
(Deogaonkar et al., 2016). Most recently, Moens et al., (2019) re-examined (fMRI) network 
functional connectivity (FC) during the resting state pre-to-post implant with paresthesia 
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free HF-SCS (at 10KHz) at one and three months (De Groote et al., 2019). Interestingly, HF-
SCS patients demonstrated an increase in FC between the right anterior insula (RAI) and 
both left lateral and dorsolateral PFC (LPFC and DLPFC). The post HF-SCS increase in FC 
of RAI to PFC is posited to indicate increases in central executive network (CEN) activity 
known to be dysregulated (decreases in FC and CEN activity) in chronic affective pain 
(Jiang et al., 2016) and inversely correlated to increased pain catastrophizing reports (Jiang 
et al., 2016). Collectively, the emerging evidence shows P-SCS and PF-SCS may 
differentially correct dysfunctional neural networks ubiquitous in the chronic pain patient.
Beside functional magnetic resonance imaging and volumetric measures, thalamocortical 
dysrhythmia (TCD) has been proposed as an underlying mechanism of chronic neuropathic 
pain and other pain disorders (Jensen et al., 2013; Llinas et al., 2005; Llinas et al., 1999; 
Sarnthein & Jeanmonod, 2008; Stern et al., 2006; Vuckovic et al., 2014; Walton et al., 2010). 
TCD is due to inhibitory asymmetries resulting from activation of cortical inhibitory 
interneurons at variable frequencies (Llinas et al., 2005; Walton et al., 2010). TCD measured 
by MEG (Rainville et al., 1997; Vogt & Paxinos, 2014; Vogt et al., 1979) and EEG 
(Vanneste et al., 2018), predominantly shows enhanced low frequency theta (5–8 Hz), as 
well as higher frequency beta (13–30 Hz) and gamma (30–60 Hz) power when chronic 
neuropathic pain patients were compared to healthy control subjects (Fig. 9). It is important 
to point out that high frequency thalamocortical oscillations underlie conscious states (beta 
13–30 Hz, and gamma 30–60 Hz), whereas increased power in persistent low-frequency 
(theta 5–8Hz and delta 1–4 Hz) activity, does not. Polymorphic low-frequency rhythms can 
result from brain lesions that interrupt important afferent inputs to the gray-matter of cortex, 
either by white matter, thalamic, hypothalamic or brainstem lesions, that suggest cortical 
slow wave activity results from cortical deafferentation (Ball et al., 1977; Gloor et al., 1977). 
Abnormal low-frequency rhythms can also be induced by the administration of atropine 
(Schaul et al., 1978). Atropine is a competitive antagonist of acetylcholine receptors and can 
block or limit the action of ACh. Together these animal experiments concluded that cortical 
deafferentation was a key factor in abnormal low-frequency activity, owing to inhibition of 
the cholinergic pathway (Schaul, 1998). Interestingly, persistent low frequency 
thalamocortical oscillations initially thought to only be present during dreamless sleep (N3 
stage) and or due to cortical deafferentation, have now also been observed in neurological 
and psychiatric conditions (chronic pain and schizo-phrenia) during wakefulness and in the 
absence of a structural lesion (Llinás et al., 2005). Moreover, patients with neuropathic pain 
demonstrate TCD phase amplitude coupling and coherence between low frequency theta and 
higher frequency beta bands localized to cortical pain processing centers, including the PFC, 
ACC and sgACC, insular cortices as well as primary (SI) and secondary somatosensory (SII) 
cortices (Stern et al., 2006). Functional neurosurgical lesioning of the thalamic central lateral 
nucleus leads to reversal of overactive TCD coherence (theta gamma and theta beta) and 
reduction in reported pain that further supports TCD as central to pain chronicity (Stern et 
al., 2006). Additional work by Shulman et al. (2005) has shown that theta power 
significantly decreased to level of healthy controls in successfully P-SCS treated CRPS 
patients while unsuccessful P-SCS showed similar theta power to untreated deafferentation 
pain syndrome patients (Schulman et al., 2005). Expanding on this work, Vannesste and De 
Ridder et al. (2018) studied source localized TCD in 78 chronic pain patients (Vanneste et 
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al., 2018) and showed: 1) increases in insular cortex and sgACC theta band power, 2) 
increases in SI and parahippocampus gamma band power, and 3) increases in theta/beta 
coherence in dorsal anterior, posterior cingulate and insular cortex (Vanneste et al., 2018) 
(Fig. 9). In a small cohort, this group found that B-SCS decreases: 1) theta and gamma band 
power in bilateral SI, 2) alpha and beta power in dorsal anterior, posterior cingulate, 3) theta 
power in the pgACC, and 4) in phase coherence between dACC and SI as well as between 
sgACC and SI (Vanneste & De Ridder, 2018). Taking into account that chronic pain patients 
exhibit TCD (Theta, Beta and Gamma band increases in power and coherence) there is a 
growing consensus that TCD could be used as a biomarker of the effects of P-SCS vs. PF-
SCS while pre-treatment coherence and power could be predictive of SCS efficacy (De 
Ridder et al., 2013; Koyama et al., 2018). Emerging preclinical work from Saab et al. 
(2018), demonstrates that PF-SCS produced a reduction of theta band power in a CCL 
neuropathic pain model. The authors argue that reduction in theta band power could be used 
as a marker for PF-SCS efficacy. De Ridder et al. (2014) demonstrated that B-SCS resulted 
in activation of dorsal ACC with increases in beta and alpha power (De Ridder et al., 2013) 
and postulated B-SCS may preferentially modulate the paleospinothalamic pathway. 
Yearwood et al. (2016, 2019) also demonstrated that B-SCS modulates the poster-ior 
anterior cingulate and subgenual cortex (Yearwood et al., 2019; Yearwood et al., 2016). 
Intriguingly, Quindlen-Hotek et al. (2019) demonstrated that B-SCS increased dorsal 
anterior cingulate firing frequency in a in a rat nerve root compression model (Quindlen-
Hotek et al., 2019). In a recent small cross-over study, our group, showed that a 5 day 
treatment with active charge bal-anced B-SCS resulted in: 1) reduction gamma and beta 
band power in the mediodorsal thalamus, and 2) a significant reduction in theta band power 
within SI SII and bilateral dorsal, mid and anterior insular cortices (Ler-man et al., 2019), 
further supporting B-SCS unique cor-tical and subcortical effects on TCD in chronic pain 
patients (De Ridder et al., 2013; Yearwood et al., 2016; Quindlen-Hotek et al., 2019). 
Although no clinical studies have been completed, preclinical work by Pawela and Hogan et 
al. (2017) have shown DRG-S attenuates fMRI BOLD neospinothalamic and 
paleospinothalamic response, including SI, SII, retrosplenial granular cortex, thalamus, 
caudate, putamen, nucleus accumbens, globus pallidus, and amygdala (Tang et al., 2014). 
Together, variations in pain processing patterns with functional neuroimaging suggest 
central maladaptive neuroplasticity in chronic pain patients contributes to the chronic pain 
experience while rich areas of research that investigate the neural effects of neuromodulation 
therapies (including P-SCS, PF-SCS and DRG-S and emerging ECAP-SCS) remain to be 
explored (Jensen et al., 2016).
P-SCS and PF-SCS mechanisms: evidence and theory
Paresthesia-based spinal cord stimulation (P-SCS)
Premised on the gate-control theory of pain, the original hypothesized mechanism of P-SCS 
was that stimulation of Aβ fibers and inhibitory interneurons led to inhibition of pathologic 
WDR neuron firing to Aδ and C fiber inputs (Melzack & Wall, 1965; Sivanesan et al., 
2018). It is now understood that multiple mechanisms contribute to P-SCS analgesia. 
Applied with a “low” frequency between 40 and 60 Hz and PW of 150–500 μs, amplitude 
and lead position are adjusted until the patient feels a tolerable, non-painful paresthesia 
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covering the target dermatome. Indicated for neuropathic pain syndromes (Linderoth & 
Foreman, 2017), P-SCS is the most extensively studied paradigm and boasts the largest body 
of evidence. Preclinical and clinical evidence for SCS efficacy is largely based on P-SCS 
and thus its mechanisms will be summarized here. At the spinal segmental level, a delivered 
pulse anti-dromically activates dorsal horn fibers as well as generates an electric field 
capable of axon depolarization in the vicinity of the dorsal cord (Yakhnitsa et al., 1999; 
Tazawa et al., 2015). It is postulated that antidromic activation of Aβ fibers contributes to 
retrograde activation of inhibitory interneurons which exert presynaptic control over PN 
firing (Zhang et al., 2014). While initially DH mapping, dorsal root potentials and TENS 
efficacy seemed to confirm this mechanism, recently the simplicity of these DH neural 
networks has come into question (Mendell, 2014; Szentagothai, 1964; Hochman et al., 
2010). The activation of DH inhibitory interneurons clearly plays a role in P-SCS-induced 
antinociception, as the lamina II inhibitory plexus arborizing to PN is the major source of 
GABA and glycine in the DH (Keller et al., 2001; Yasaka et al., 2007). With P-SCS, an 
increase in DH GABA and decrease in glutamate via presynaptic GABA inhibition is critical 
to improvement in allodynic rat models (Yakhnitsa et al., 1999; Cui et al., 1996; Stiller et al., 
1995) (Fig. 4). However, the origin of inhibitory interneuron activation remains uncertain. 
Currently, it is unclear the degree to which descending inputs, antidromic activation via Aβ 
afferents and direct modulation by a localized electric field each affect the inhibitory action 
of interneurons (Elbasiouny & Mushahwar, 2007; Francis et al., 2003; Jefferys et al., 2003). 
Studies of intact, decerebrate and cord-transected models each demonstrate efficacy with 
SCS, arguing for multiple contributions to the dorsal horn inhibitory circuit (Saade et al., 
1985; Saade et al., 1986).
P-SCS may attenuate gliosis and glial-mediator release, inflammatory and maladaptive 
responses to neural injury contributing to allodynia and hyperalgesia (Ji et al., 2013). 
Closely interlinked with neurons in the proposed tripartite synapse, glia are responsible for 
contributing input via secretion of bioactive mediators which results in increased excitatory 
and decreased inhibitory post-synaptic currents after nerve injury (Fig. 6) (Mika et al., 2013; 
Araque et al., 1999). Modulation of gliosis, glial-mediator release and neuroinflammation is 
a largely unexplored potential mechanism of P-SCS-mediated analgesia. Currently, the 
limited body of evidence suggests low frequency P-SCS decreases microglia and astrocyte 
activation, though little is known about changes in local glial mediators (Sato et al., 2014; 
McCarthy & McCrory, 2014a). Some work has been performed evaluating peripheral 
inflammation in CRPS patients showing reduced cytokine levels measured in the peripheral 
tissues, but it is unclear whether this work will translate to the DH (Kriek et al., 2018). 
Given that P-SCS likely reduces gliosis and peripheral inflammation, SCS attenuation of 
gliosis and glial mediator release is an exciting area for further investigation.
Orthodromic activation of the dorsal columns also facilitates antinociception through 
triggering of supraspinal inhibitory loops, colloquially referred to as the serotonergic and 
noradrenergic DAS (Fig. 5) (Saade et al., 1986; Tazawa et al., 2015). Stimulation of these 
descending pathways leads to increases in DH serotonin and NE, which limit PN firing 
through a GABAergic mechanism. Activation of the serotonergic DAS by P-SCS leads to 
increased DH 5-HT, and subsequently GABA and glycine (Cui et al., 1997; Stiller et al., 
1996; Cui et al., 1996). It is likely that the serotonergic DAS plays a greater role in P-SCS-
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mediated antinociception than the noradrenergic DAS, the role of which needs to be further 
clarified (Song et al., 2013b). Additionally, the analgesic effect of opioids likely includes the 
recruitment of the noradrenergic DAS (Tazawa et al., 2015). Opioidergic mechanisms 
contribute to P-SCS-mediated analgesia with frequency-dependent, differential activation of 
opioid receptor subclasses (Sato et al., 2013). Moreover, there may be a development of 
tolerance to opioidergic recruitment as well as an opioidergic ceiling effect of maximal 
benefit, which should be further investigated (Chandran & Sluka, 2003; Inoue et al., 2017). 
The site of action and mechanism of P-SCS opioidergic recruitment remains to be 
determined. While the presence of the DAS and supraspinal relationships continue to be 
heavily investigated, the DH neural circuitry, and relative contribution of descending targets 
remain to be fully elucidated. Though our understanding of the involvement of segmental 
and supraspinal mechanisms of P-SCS-induced analgesia has dramatically improved, further 
research is needed to clarify the role and necessity of each of these mechanisms in regard to 
overall antinociception.
High frequency spinal cord stimulation (HF-SCS)
Paresthesia-free high frequency SCS (HF-SCS) refers to kilohertz-frequency impulses 
delivered via percutaneously placed epidural electrodes. Having level I evidence for patients 
with back or leg pain, HF-SCS at 10 kHz showed superiority to P-SCS in two separate 
randomized clinical trials (Kapural et al., 2015; Kapural et al., 2016). In stark contrast to P-
SCS, HF-SCS employs a paresthesia-free charge delivery strategy exploiting the strength-
duration curve, delivering high frequency and low amplitude pulses to maximize total charge 
delivery without generating a paresthesia (Kapural et al., 2015). Pain relief with HF-SCS 
does not correlate to territory of paresthesia, supporting a novel MOA. Further evidence for 
this stems from clinical data demonstrating early pain relief with traditional SCS compared 
to delayed relief with kHz frequency stimulation (Chakravarthy et al., 2018b). While 10 kHz 
stimulation is the most commonly employed delivery strategy, evidence for efficacy with 
sub-threshold lower-frequency paradigms including 1 kHz, 1.15 kHz, and 5 kHz have 
demonstrated benefit over P-SCS (Youn et al., 2015; North et al., 2016; Perruchoud et al., 
2013). In 2018, the PROCO RCT published their data on HF-SCS, finding no difference in 
outcomes for interval frequencies from 1 to 10 kHz (Thomson et al., 2018). Though the 
mechanisms of pain relief with HF-SCS remain to be elucidated, Linderoth et al. (2017) 
evaluated 3 working hypotheses initially presented at the 2016 Neuromodulation: The 
Science meeting (Linderoth & Foreman, 2017). These listed hypothesis report HF-SCS 
results in: 1) a reversible depolarization blockade, 2) desynchronization of neural signals and 
3) membrane integration, although others propose a mechanism of glial-neuronal 
modulation (Linderoth & Foreman, 2017; Chakravarthy et al., 2018b). While depolarization 
blockade and membrane integration offer a reasonable physiologic explanation of SCS 
relief, Lempka et al. (2015) employed neuronal modeling that demonstrated direct activation 
or conduction block of DH or DRG neurons required a higher amplitude than the current 
clinical devices are capable of delivering (Lempka et al., 2015). In support of this assertion, 
follow up pre-clinical work demonstrated a lack of DH block as well as a lack of DH 
activation with sub-threshold HF-SCS (Song et al., 2014). Crosby et al. (2016) showed that 
only supra-motor threshold HF-SCS resulted in a reliable antidromic or orthodromic AP 
recording, further suggesting HF-SCS must employ alternative mechanism to known 
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Hodgkin-Huxley neuronal models (Crosby et al., 2016). Similarly, Song et al. (2014) 
showed sub-threshold HF-SCS is unable to evoke action potentials to DH nuclei and instead 
proposed that its MOA is likely segmental and does not involve the supraspinal mechanisms 
seen in P-SCS (Song et al., 2014). Consistently demonstrated in both preclinical work and 
clinical experience, the antinociceptive effects of HF-SCS inevitably have a delayed onset in 
comparison to P-SCS (Shechter et al., 2013). Having taken this delay into account, 
McMahon et al. (2016) applied 20% motor threshold at 10 kHz frequency in close proximity 
to DC that showed significant reduction in windup of superficial DH PN (McMahon & 
Smith, 2016). Of note, applying 20% motor threshold to the DC does not activate Aβ-fibers 
and is also very unlikely to generate any relevant paresthesia in clinical settings. Using the 
same SCS paradigm, Kagan et al. (2018) showed treatment with HF-SCS at 20% motor 
threshold reduced DH PN activity with depressed firing up to 4 min after HF-SCS had 
ceased (Kagan et al., 2018). Further, Li et al. (2018) showed that application of 500 Hz DC 
stimulation increased DH c-Fos, providing further support that HF-SCS modulates dorsal 
horn neural circuits (Shiyeng et al., 2018). While the effects of HF-SCS on DH circuitry 
have been somewhat clarified, the mechanisms by which these changes occur remain 
nebulous. Of particular note, work by Zannou et.al. (2019) demonstrates that HF-SCS 
applied at 10 kHz resulted in significant local heating (Zannou et al., 2019). The authors 
postulate that local temperature increase in response to HF-SCS may result in thermal 
homeostatic changes and potentially provides an explanation for the delayed onset of pain 
relief by HF-SCS (Thomson et al., 2018; Al-Kaisy et al., 2015). Specifically, they 
hypothesize HF-SCS modulates neuroinflammation through changes in 72 kDa heat shock 
protein (Hsp70), known to inhibit activation of proinflammatory transcription factors in SGC 
(Zannou et al., 2019). Together, converging lines of evidence support the direct effect of HF-
SCS on local dorsal structures in the spinal cord, likely contributing to the clinical effects of 
HF-SCS. While the effects of P-SCS on glial-neural modulation have been demonstrated, 
the effects of HF-SCS on glial synaptic modulation remain to be studied. Moreover, to date 
there is a relative absence of literature evaluating the supraspinal mechanisms of HF-SCS, 
including those measured by neuroimaging or direct measurement of neurotransmitters and 
local mediators. Further work is clearly needed to elucidate these mechanisms.
Burst spinal cord stimulation (B-SCS)
Predominantly paresthesia-free in the majority of patients with neuropathy, B-SCS employs 
a stacked pulse paradigm for charge delivery (De Ridder et al., 2010; Deer et al., 2018; Schu 
et al., 2014; Tang et al., 2014) (Fig. 10). Endogenous neuronal burst firing is ubiquitous 
throughout the neuraxis and results in activation of either subthreshold membrane 
conductance initiating AP or a supra-threshold membrane conductance that once activated 
evokes two or more AP. These high-frequency AP occur during a plateau or active phase and 
are followed by a period of relative quiescence, termed the silent phase. During the silent 
phase, slow Ca2+ channel opening results in threshold depolarization via Na+ and Ca2+-
activated conductance that is inherent to neuronal burst firing. Relevant neuronal targets that 
exhibit burst firing have consistently been identified in the mediodorsal thalamic (Hodaie et 
al., 2006) and dorsal horn neurons (Russo & Hounsgaard, 1996; Lopez-Garcia & King, 
1994), suggesting that neuronal burst firing plays a role in both the neo and 
paleospinothalamic pathways, while afferent C tactile fibers also exhibit bursting firing 
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(Liljencrantz & Olausson, 2014). In the DH, a majority of bursting cells are found in lamina 
I, while bursting neurons of the dorsomedian nucleus project third order neurons to the ACC 
(Hodaie et al., 2006), previously shown to be modulated by B-SCS (De Ridder et al., 2013). 
Multiple thalamo-cortical relays demonstrate thalamic burst firing. An initial burst can result 
in greater ability to elicit cortical AP, while repeated burst firing raises the probability of an 
aggregate increase in thalamo-cortical summative signals, potentially increasing the salience 
of that signal (Swadlow & Gusev, 2001; Sherman, 2001). Moreover this summative signal 
undergoes “multiplexing”, meaning that certain neuron ensembles will preferentially activate 
when receiving particular burst frequencies, while other neuronal ensembles may remain 
quiescent (Izhikevich et al., 2003). In clinical B-SCS, frequencies consist of 40-Hz bursts 
with five spikes at 500-Hz spike frequency, a pulse width of 1000 μs, and an inter-burst 
interval of 1000 μs (Fig. 10). By design, B-SCS emulates endogenous neuronal bursting 
patterns. B-SCS waveforms replicate endogenous burst-firing Na+ spikes that ride on a 
Ca2+-dependent plateau. This eventually becomes charge balanced after the high-frequency 
spikes are terminated. For instance, neurons of the dorsomedian nucleus demonstrate a mean 
burst duration of 1000–1600 μs with approximately 3 to 5 spikes per burst that is in line with 
the De Ridder B-SCS paradigm (De Ridder et al., 2013). Interestingly, Crosby et al. (2015) 
showed larger pulse widths incrementally increase B-SCS analgesia in preclinical rat SNL 
models (Crosby et al., 2015b; De Ridder et al., 2018). Of note, inter-burst frequency 
employs the most common P-SCS treatment frequencies (i.e., 40 Hz) while the intra-burst 
frequency of 500 Hz parallels that of HF-SCS paradigms. In a rat SNL model treated with 
B-SCS, Crosby et al. (2015) determined that changes in inter-burst frequency (comparing 
20, 40 and 60 Hz) did not incrementally decrease DH excitability. Interestingly, they did 
note that increasing the number of pulses per burst correlated with reduced DH activity 
(Crosby et al., 2015b). This is in line with preclinical literature that shows that increasing the 
number of pulses per burst: 1) incrementally increases the nonlinear buildup of the 
postsynaptic potential, 2) improves signal to noise ratio, and 3) results in enhanced 
neuroplasticity. However, less effects are seen at greater than 6–7 spikes per burst, indicating 
a ceiling effect (Snider et al., 1998). In support of this construct, Kent et al. (2017) further 
showed incremental increases in each pulse amplitude over the course of each burst resulted 
in summative increases in ECAP (Kent et al., 2017). Further in line with this finding, Gong 
et al. (2016) indicated that incremental increases in the intraburst frequency were more 
efficacious than P-SCS, measured with increased PWT in a rat SNL model (Gong et al., 
2016). De Ridder et al. (2018) suggest that intraburst frequency of 500 Hz is critical for 
efficacy, citing work by Song et al. (2008) that showed higher frequency was inductive of 
maximal SCS opioidergic effects, although this finding has not been replicated in pre-
clinical B-SCS models (Song & Marvizón, 2003). Crosby et al. (2015) further reported that 
increases in B-SCS amplitude incrementally decrease DH excitability. In aggregate, pulses 
per burst and pulse width parameters constitute the charge density, which has been shown as 
a predictor of B-SCS efficacy (Crosby et al., 2015b). Besides effects in the DH, Tang et al. 
(2014) reported P-SCS action on WDR and low-threshold (LT) neurons within the gracile 
nucleus; however, B-SCS had no significant impact on gracile neuronal firing (Tang et al., 
2014). Nonetheless, the authors showed that B-SCS outperformed P-SCS, showing greater 
analgesic effects when measured with the visceromotor reflex challenge (Tang et al., 2014). 
Meuwissen et al. (2018) recently compared analgesic effects of B-SCS to P-SCS in a SNL 
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rat model, while also comparing charge per second for each SCS paradigm. Introducing 
temporal charge domain measures, their group showed that although B-SCS was equally 
effective to P-SCS at lower motor threshold, B-SCS employed a relatively greater charge per 
second to achieve equivalent analgesic effects (Meuwissen et al., 2018). Interestingly, while 
segmental GABAergic effects are paramount to P-SCS efficacy, they are differentially 
regulated in B-SCS (Tables 1 and 2). Crosby et al. (2015) showed that although B-SCS and 
P-SCS both attenuated evoked WDR neuron activity to noxious stimuli, administration of a 
GABAB receptor antagonist abolished attenuation of WDR activity in P-SCS but not B-SCS 
(Crosby et al., 2015b). Moreover while P-SCS increased serum GABA concentrations, this 
was not observed with B-SCS, indicating a diverging mechanism (Crosby et al., 2015b). 
While the authors accept that serum GABA levels are not necessarily reflective of CNS 
GABA concentrations, these results nonetheless suggest that B-SCS analgesia is likely 
mediated through non-GABAergic mechanisms. To date, no published studies have 
determined the effect of B-SCS on 5-HT, NE or endogenous opioid pathways. Though Kinfe 
et al. (2018) did show an increase serum IL-10 with B-SCS, it is difficult to substantiate 
these findings as representative of actual inflammatory-mediated change in the CNS (Kinfe 
et al., 2017). As mentioned, electrical pulses applied to thoracic spinal cord are not likely to 
directly modulate systemic effects of cytokines levels, however indirect attenuation of pain, 
changes in mood, or improvement in sleep may result in these observed anti-inflammatory 
effects (Lerman et al., 2016; Irwin et al., 2006; Irwin & Cole, 2011; Slavich & Irwin, 2014). 
Although it is difficult to determine the direct neuronal effects of B-SCS on supraspinal and 
cortical attentional mechanisms, as Tang et al., (2014) reported an absence of gracile 
neuronal activity, B-SCS may modulate dorsal column and dorsal horn activity. De Ridder et 
al. (2018), postulated that B-SCS 1) modulates low-threshold, tactile C-fibers that are known 
to be antinociceptive and 2) mediates multiplexing which could contribute to supraspinal 
analgesic and modulation of cortical attentional mechanisms (Liljencrantz & Olausson, 
2014; Izhikevich et al., 2003; De Ridder et al., 2018). In support of B-SCS supraspinal 
cortical effects, Meuwissen et al. (2019) developed and validated the first preclinical operant 
motivational testing method that assessed affective-motivational aspects of pain in 
neuropathic rat models treated with SCS. In this model, the animal must brave a nociceptive 
challenge: crossing over noxious probes from an aversive brightly lit chamber to receive the 
reward, a dimly lit chamber. Implicating that B-SCS specifically modulates supraspinal 
cognitive affective-emotional circuits, they showed biphasic B-SCS improved exit time from 
the aversive chamber more than P-SCS, with no difference in measured PWT. This seminal 
work represents a truly novel preclinical model that may further translate our clinical 
observations. Due to remaining large knowledge gaps regarding these mechanisms, there is a 
clear need for the pain community to continue investigating these promising avenues (De 
Ridder et al., 2013; Yearwood et al., 2016; Quindlen-Hotek et al., 2019; Lerman et al., 
2019). The clinical and scientific community should remain committed to clarifying the 
process by which B-SCS imparts clinical efficacy, with particular regard to segmental, 
supraspinal and inflammatory mechanisms.
Dorsal root ganglion stimulation
Dorsal root ganglion stimulation (DRG-S) is an emerging neuromodulation target made 
possible by continued neurotechnology advancements, with increasingly more steerable and 
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flexible leads (Liem et al., 2013). The intentional neuromodulation of the DRG has been 
described as early as 1998 and 1999 (Alo et al., 1999; Wright & Colliton, 1998). However, 
reports in the literature have been appearing more consistently only within the past 5 years 
(Harrison et al., 2018) (Hunter et al., 2019)). The DRG is located in the lateral epidural 
space and contains the cell bodies of the sensory neurons, crucial for the transduction of pain 
(Koopmeiners et al., 2013; Van Buyten, 2018) (Fig. 1). As described above, pathologic 
changes occur within the sensory neurons in chronic pain states, such as increased firing 
rates, making them a potential target for stimulation. While the evidence has shown 
traditional SCS can provide substantial relief for multiple painful conditions, it has 
limitations inherent to its physical location within the spine and its delivery of the therapy 
(Liem et al., 2013; Harrison et al., 2018; Deer et al., 2013). SCS electrodes are traditionally 
placed in the posterior epidural space. Even when considering the multiple modalities as 
reviewed above - traditional, high frequency, and burst stimulation – they all deliver the 
energy targeting the posterior spinal cord tracts, and not the sensory neurons themselves. 
This has been useful for coverage of an entire limb pain, and diffuse neuropathies; however, 
it can make coverage of specific targets difficult, such as pelvic pain, mononeuropathies, 
back pain, and unilateral and/or distal limb pain (Harrison et al., 2018; Van Buyten, 2018). 
DRG stimulation allows for more specific delivery of therapy to the affected dermatomes or 
pain regions.
A recent in vitro animal study of DRG-SCS demonstrated an alteration in Ca2+ influx 
slowed nerve conduction velocity, reduced action potential propagation and neuronal 
excitability as possible mechanism of action (Koopmeiners et al., 2013). In this way, DRG-S 
provides analgesia by blocking APs induced from the periphery, as well as the pathologic 
ectopic activity in the neuronal cell body. Further, Pawela et al. (2017) demonstrated 
changes on functional magnetic resonance imaging (fMRI) in a rat animal model, with 
attenuation in the regions of the brain associated with response to noxious stimuli 
(Koopmeiners et al., 2013; Pawela et al., 2017; Kramer et al., 2018). As compared to the 
control group, the response to noxious stimuli in the primary/secondary somatosensory 
cortex, retrosplenial granular cortex, thalamus, caudate putamen, nucleus accumbens, globus 
pallidus, and amygdala was attenuated with DRG-S. Interestingly, they further confirmed 
their findings with high-intensity (above treatment level) DRG-S, which produced a signal 
map similar to an acute noxious stimulation. Pan et al. (2016) studied DRG-S in an rat 
animal model of induced neuropathic pain from a sciatic nerve injury (Pan et al., 2016). 
They demonstrated that DRG-S reversed mechanical and cold hypersensitivity in the 
neuropathic pain state by animal behavioral response to the stimuli. Animals receiving 
DRG-S lacked the elevated expression of injury markers present in the positive injury 
control (Pan et al., 2016). Markers of glial cell activation and neuronal injury, respectively, 
GFAP and ATF-3 were similar between normal uninjured DRG and DRG with stimulation. 
This finding is remarkable, as GFAP and ATF-3 were both elevated in the positive injury 
control (Pan et al., 2016). Currently, there are multiple published studies that demonstrating 
the efficacy of DRG-S in humans. Fourteen studies were reviewed in 2018 by Harrison and 
colleagues, which demonstrated promising outcomes (Harrison et al., 2018). The 
ACCURATE RCT examined the efficacy of DRG-S compared to traditional SCS in patients 
with CRPS, and found DRG-S to be significantly superior in treating pain. The placement of 
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the DRG electrodes within the neural foramen is widely accepted as being technically 
difficult, with a higher learning curve than traditional SCS and potentially more painful 
intra-procedurally (Van Buyten, 2018; Deer et al., 2013). The use of DRG-S is currently 
limited to practitioners who have completed specific training and demonstrated competency 
with the device, while its adoption is rapidly increasing in the United States.
Closed-loop evoked compound action potentials
By combining the understanding of antidromic stimulation from SCS affecting SSEP, 
involuntary sensorimotor reflexes and correlation with treatment efficacy, further research 
has been done involving ECAP as a method of both studying and modifying the delivery of 
SCS therapy. ECAP is the neurophysiologic recording of the response of nerve fibers to a 
stimulus (Russo et al., 2018; Guan et al., 2018)). More specifically, it is an ion measurement 
along the membranes of the nerve’s axon, which occurs during an AP, which subsequently 
generates the electric field to be recorded (Russo et al., 2018; Guan et al., 2018; Laird & 
Parker, 2013). Thus, the conduction velocity, amplitude, fiber diameter, and number of 
recruited fibers can be calculated (Guan et al., 2018). Additionally, the excitability and 
frequency of the AP can be used to infer the type of pain the patient is experiencing. For 
example, repetitive neuronal discharges and increases in sensory fiber excitability have been 
linked to chronic neuropathic conditions (Devor, 2009). The leads of P-SCS are in an ideal 
position to measure the ECAP of the dorsal columns as they lay just posterior in the epidural 
space. In this way, the non-stimulating electrodes can be modified to measure the ECAP of 
the axons being stimulated (Guan et al., 2018; Laird & Parker, 2013). This opens up the 
possibility of both studying the effects on neuronal tracts to further understand mechanisms 
of action of the multiple SCS paradigms, as well optimizing the treatment for the patient to 
improve efficacy. The feasibility of using P-SCS leads to measure ECAP was demonstrated 
in both an animal and human model by Parker and colleagues (Parker et al., 2013; Parker et 
al., 2012). Both studies confirmed the previously held theory that P-SCS primarily recruits 
large diameter Aβ fibers and that the ECAP amplitude increases with increasing current 
delivered by the leads. By utilizing this closed-loop measurement, ECAP can function as a 
feedback control to adjust dorsal column fiber recruitment, allowing the device to adjust 
delivered current in order for patients remain in the therapeutic window throughout 
treatment, while avoiding unnecessary and potentially uncomfortable overstimulation. While 
one open-label study found benefit, further study of efficacy and feasibility of this 
technology as a therapeutic option is needed (Russo et al., 2018) (Fig. 11).
Conclusion
With accelerated interest in novel paradigms and neural targets, the rapid evolution of SCS 
has helped define the field of bioelectronic medicine. This comprehensive review was 
undertaken in order to arm the clinician-scientist with the most up-to-date evidence with 
which to evaluate the proposed and accepted mechanisms of modern SCS. More 
importantly, we sought to expose gaps in our understanding of these therapies and to identify 
potentially fruitful and unexplored avenues for future investigation. At this juncture, it is 
crucial to continue elucidating the mechanisms of P-SCS, PF-SCS, DRG-S and ECAP-SCS. 
Doing so may potentially lead to new or synergistic therapies for patients with debilitating 
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chronic pain syndromes. Here, we reviewed the evidence and theory for the analgesic 
mechanisms of modern SCS. Specifically, we evaluated the modulation of 1) segmental and 
supraspinal neurotransmitters, 2) segmental and supraspinal neurophysiology/
neuroplasticity, 3) central and peripheral neuroinflammation and 4) cortical and subcortical 
neurocircuits (Fig. 12). Moreover, further research is needed to characterize widely 
heterogenous pathophysiological processes that contribute to the progression and 
maintenance of chronic pain. These heterogenous pathological processes can evolve over 
time; however current SCS paradigms remain temporally fixed. Promising new SCS 
paradigms such as ECAP-SCS, DRG-S and the selective use of combined simultaneous P-
SCS and PF-SCS may employ multiple, synergistic and adaptive mechanisms, thus opening 
the door to precision-based SCS aimed at specific pathogenic processes. In total, SCS is a 
safe and effective therapy for patients with neuropathic pain conditions and FBSS, which is 
currently undergoing rapid evolution. The clinical evidence supporting SCS is 
overwhelmingly positive while the level of evidence has steadily improved during the advent 
of HF-SCS, B-SCS and DRG SCS. With promising emerging paradigms such as ECAP-SCS 
and DRG-S as well as an arsenal of SCS therapies, the pain physician is responsible for 
making a weighty decision, the consequence of which may lead to an invasive procedure and 
subsequent device implantation for the patient. To substantiate this clinical choice, there is 
an urgent need to complete careful, systematic preclinical mechanistic and evidence-based 
clinical research to close our sizable knowledge gaps.
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Abbreviations
5-HT 5-Hydroxytryptamine, Serotonin
A5 Noradrenergic Cell Group A5
A7 Noradrenergic Cell Group A7
ACh Acetylcholine
AEN Affective-emotional network
AI Anterior Insula
AMPA Amino-3-hydroxy-5-methyl-4-isoxazole propionate
Amy Amygdala
AP Action potential
ATF3 Activating transcription factor 3
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BDNF Brain-derived neurotrophic factor
CB Charge-balancing
CC Current-Controlled
CCI Chronic constriction injury
c-Fos Proto-oncogene
CGRP Calcitonin Gene-related Peptide
CGRPR Calcitonin Gene-related Peptide Receptor
CPM Conditioned pain modulation
CRPS Chronic Regional Pain Syndrome
CS Central sensitization
CSF Cerebrospinal Fluid
CXCL16 Chemokine C-X-C Motif Ligand 16
dACC Dorsal Anterior Cingulate Cortex
DAS Descending antinociceptive systems
DCML Dorsal column medial lemniscus
DH Dorsal Horn
DLF Dorsal Lateral Funiculus
DM Dura Mater
DMN Default mode network
DNIC Diffuse noxious inhibitory control
dPI Dorsoposterior Insula
DRG-S Dorsal Root Ganglion Stimulation
ECAP-SCS Evoked Compound Action Potential-SCS
EEG Electroencephalogram
EF Electric Field
FBSS Failed Back Surgery Syndrome
fMRI Functional Magnetic Resonance Imaging
GABA Gamma-aminobutyric Acid
GABAR Gamma-aminobutyric Acid Receptor
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GDNF Glial Cell Line-Derived Neurotrophic Factor
GFAP Glial fibrillary acidic protein
Glu Glutamate
Gly Glycine
GlyR Glycine Receptor
HF-SCS High Frequency Spinal Cord Stimulation
Hz Hertz
IC Insular cortex
IF Interstitial Fluid
IFN-γ Interferon Gamma
IL-10 Interleukin 10
II-12 Interleukin 12
IL-13 Interleukin 13
IL-15 Interleukin 15
IL-17 Interleukin 17
IL-1β Interleukin 1β
IL-2 Interleukin 2
IL-6 Interleukin 6
IL-8 Interleukin 8
INS Insula
IPG Implantable Pulse Generator
LC Locus Coeruleus
LTP Long Term Potentiation
MCP-1 monocyte chemoattractant protein 1
MEG Magnetoencephalography
mGLU Metabotropic glutamate
MOA Mechanism of Action
NE Norepinephrine
NGF Nerve Growth Factor
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NK1 Neurokinin-1
NK1 Neurokinin-1
NK1R Neurokinin-1 Receptor
NMDA N-methyl-D-aspartate
NpY Neuropeptide Y
NS Nociceptive Specific
OFC Orbitofrontal cortex
PAG Periaqueductal gray
PCC Posterior Cingulate Cortex
PFC Prefrontal Cortex
PF-SCS Paresthesia Free Spinal Cord Stimulation
pgACC Perigenual Anterior Cingulate Cortex
PHC Parahippocampus
PN Projection Neuron
PNS Peripheral nervous system
P-SCS Paresthesia Spinal Cord Stimulation
PW Pulse width
QST Quantitative sensory testing
RI Rostral Insula
RIII Flexor reflexes
RVM 5-HT Like RVM 5-HT Like cells projecting from RVM to DH
RVM OFF Rostral ventromedial medulla OFF cells
RVM ON Rostral ventromedial medulla ON cells
RVM Rostral ventromedial medulla
SC Spinal Cord
SCS Spinal Cord Stimulation
SDN Sensory-discriminative network
SG Substantia gelatinosa
SGC Satellite glial cells
Caylor et al. Page 38
Bioelectron Med. Author manuscript; available in PMC 2019 August 21.
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
SI Primary Somatosensory Cortex
SII Secondary Somatosensory Cortex
SNI Spared nerve injury
SNL Spinal nerve ligation
SP Substance P
SSEP Somatosensory evoked potentials
STT Spinothalamic tract
TCD Thalamocortical dysrhythmia
TENS Transcutaneous electrical nerve stimulation
TGF-β Transforming Growth Factor Beta
TNF-α Tumor Necrosis Factor Alpha
TrkB Tropomyosin receptor kinase B
TS Temporal summation
VC Voltage-Controlled
VEGF Vascular Endothelial Growth Factor
VIP Vasoactive Intestinal Peptide
VLF Ventrolateral Funiculus
VPL Ventral Posterior Lateral nuclei of the thalamus
VPM Ventral Posterior Medial nuclei of the thalamus
WDR Wide Dynamic Range
α Alpha
β Beta
γ Gamma
θ Theta
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Fig. 1. 
Lead Placement in P-SCS and PF-SCS: Dorsalcolumn stimulation with traditional P-SCS, 
B-SCS and HF-SCS are anatomically placed over the dorsalcolumns. DRG-S is placed 
within the targeted foramina overlying the dorsalroot ganglion. In all cases SCS can result in 
orthodromic activation or antidromic activation. Acronyms: IPG (Implantable Pulse 
Generator)
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Fig.2. 
Parameters for SpinalCord stimulation: Panel a: Amplitude: the peak current delivered, 
measured in milliamperes (mA). This impacts the number of fibers recruited and intensity of 
paresthesia. Amplitudes that are subthreshold do not generate an action potentialand thus do 
not create paresthesia. Pulse Width (PW): the time over which the current is delivered, 
measured in microseconds (μs). The PW determines the amount of charge delivered for a 
given amplitude. Mathematical integration of the charge waveform yields the totalcharge 
delivered per pulse, measured in nanocoulombs. Increases in PW may recruit additional Aβ 
Fibers and broaden the area of paresthesia. Frequency: the number of pulses per second, 
measured in hertz (Hz). Panel b: Burst SCS parameters describing inter-burst frequency, or 
the number of bursts per second, and intraburst frequency, describing the number of pulses 
within a burst, measured in Hz. Panel c: The waveform or shape of the pulse can be divided 
into two segments: depolarization, or deflection above electroneutrality, and repolarization, 
the return to baseline. The depolarization waveform is determined by whether the system 
delivers the pulse in a Current-Controlled (CC) or Voltage-Controlled (VC) fashion. Current 
describes the flow of charge whereas voltage describes the potential difference between 
electrodes
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Fig. 3. 
Mechanisms of Hyperalgesia and Allodynia. Panel a) Non-pathologic nociception whereby 
C-fiber and Aβ inputs relay through an interneuron to modulate ascending signals via the 
projection neuron. Panel b) Nerve injury or repeated peripheral c-fiber stimuli leads to 
centralsensitization through multiple mechanisms including changes in receptor kinetics, 
resting membrane potential and phenotypic transformation of Aβ afferent fibers. Through 
long term potentiation and altered receptor expression at the post receptor density zone, 
subthreshold stimulation evokes action potentials leading to classic hyperalgesia. Aβ axon 
sprouting after injury and secretion of substance P may offer further explanation for the 
development of tactile allodynia. Acronyms: Glu (Glutamate), Gly (Glycine), GABA 
(gamma amino butyric acid), SP (Substance P), BDNF (Brain Derived Neurotrophic Factor), 
CGRP (Calcitonin Gene Related Peptide), MGLUR (metabotropic glutamate receptor), 
TRKB (Tropomyosin receptor kinase), GABAR (GABA Receptor), AMPAR (AMPA 
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Receptor), CGRPR (CGRP Receptor), NMDAR (NMDA Receptor), NK1R (Neurokinin-1 
Receptor), LTP (Long Term Potentiation)
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Fig. 4. 
Changes in Dorsal Horn Circuitry to chronic pain and SCS. In the development of chronic 
pain, neural circuitry undergoes rewiring wherein abnormal enhancement of excitatory 
pathways and loss of inhibition facilitate nociceptive transmission to sub-threshold stimuli. 
Increased excitatory interneuron input, decreased inhibitory interneuron input and local 
factors contribute to pathologic destabilization of normal input balance to the projection 
neuron. SCS changes the balance of nociceptive and antinociceptive inputs through the 
activation of local segmental and descending supraspinal mechanisms to in-part restore 
balance to this network. Acronyms: DCN (DorsalColumn Nuclei), E (Excitatory 
Interneuron), I (Inhibitory Interneuron), PN (Projection Neuron), SP (Substance P), Glu 
(Glutamate), GABA (Gamma Aminobutyric Acid), 5-HT (5-Hydroxytryptamine, Serotonin)
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Fig. 5. 
Supraspinal Mechanisms of Spinal Cord Stimulation. A hallmark of chronic pain, abnormal 
enhancement of excitatory pathways and a loss of inhibition facilitate nociceptive 
transmission to sub-threshold stimuli. With SCS, orthodromic activation of 
supraspinalcenters of pain control facilitates antinociception through activation of the DAS, 
largely through recruitment of the PAG, RVM and LC. Increases in spinal ACh, 5-HT and 
GABA as well as decreased spinal glutamate with SCS are in part thought to be a result of 
descending pathway recruitment. ‘Up’ arrows represent increased concentration or activity, 
whereas ‘down’ arrows represent opposite. ‘Sideways’ arrows represent no change. 
Acronyms: PAG (Periaqueductal Gray), RVM (RostralVentromedial Medulla), LC (Locus 
Coeruleus), A5 (Noradrenergic CellGroup A5), A7 (Noradrenergic Cell Group A7), DH 
(Dorsal Horn), DC (Dorsal Column), VLF (Ventrolateral Funiculus), DLF (Dorsolateral 
Funiculus), RVM ON (RVM On cells projecting from the RVM to the DH), RVM OFF 
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(RVM OFF cells projecting from the RVM to the DH), RVM 5-HT Like (RVM 5-HT Like 
cells projecting from RVM to DH), cFOS (proto-oncogene), E (Excitatory Interneuron), I 
(Inhibitory Interneuron), PN (Projection Neuron), Glu (Glutamate), 5-HT (5-
hydroxytryptamine), ACh (Acetylcholine), NE (Norepinephrine), GABA (Gamma 
Aminobutyric Acid)
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Fig. 6. 
Local Glia Modulate Synaptic Transmission After Nerve Injury. Glia are intimately 
associated with spinalexcitatory and inhibitory synapses. The release of cytokines and 
glialmediators on pre and post-synaptic terminals modulates the activity of that synapse. 
Cytokines released at glutaminergic excitatory synapses augment transmission while 
cytokines released at GABAergic and Glycinergic synapses attenuates the signal. The net 
effect of gliosis and release of glial mediators is an increase in spinal cord pain transmission. 
Novel modes of SCS may modulate glial activity, thereby enacting their antinociceptive 
mechanisms through this pathway. Acronyms: Glu (Glutamate), GABA (Gamma 
Aminobutyric Acid), Gly (Glycine), TNF-α (Tumor Necrosis Factor Alpha), IL-1β 
(Interleukin 1β), IFN-γ (Interferon Gamma), NMDAR (NMDA Receptor), AMPAR 
(AMPA Receptor), BDNF (Brain Derived Neurotrophic Factor), GABAR (GABA 
Receptor), GlyR (Glycine Receptor), PGE2 (Prostaglandin E2)
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Fig. 7. 
Neurophysiological testing. Somatosensory evoked potentials (SSEP) waveforms are 
measured by applying an electricalstimuli to the tibial nerve. SSEP waveforms recorded with 
scalp electrodes at (CPz-Fz) are modulated with SCS. Panel a: During SCS ON P39-N50-
P60 representative SSEP waveform decreases in amplitude. Flexor reflexes (RIII) are 
obtained with noxious electrical stimuli are applied to the suralnerve. The RIII waveform is 
recorded from the ipsilateral biceps femoris. Panel b: During SCS ON there is decrease the 
amplitude of the RIIIwaveform (adapted from (Sankarasubramanian et al., 2018b)). 
Quantitative sensory testing (QST) applies different sensory stimuli, such as vibratory, 
tactile or thermal stimuli to the subject extremity. Panels c, d: SCS results in variable effects 
on QST sensory thresholds and may increase increases pain threshold and tolerance. 
Advanced QST measures including temporal summation (TS) and conditioned pain 
modulation (CPM) can provide further insight into P-SCS, PF-SCS and DRG-S analgesic 
mechanisms
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Fig. 8. 
Cortical and Sub-cortical Pain Processing. Sensory-discriminative pain processing with 
thalamus, SI, SII and posterior IC, with sensory discriminative pain relayed through the 
ventroposterior-lateral and ventroposterior-medial thalamic nuclei and is also termed the 
neospinothalamic pathway. Affective-emotional pain processing with dorsal ACC and 
Anterior IC while affective sensory information to the AEN is thought to be relayed through 
the medio-dorsal thalamus, also termed the paleospinothalamic pathway. PFC (Prefrontal 
Cortex), OFC (orbitofrontal cortex) SI (Primary Somatosensory Cortex) SII (Secondary 
Somatosensory Cortex) dACC (Dorsal Anterior Cingulate Cortex) Amy (Amygdala), AI 
(Anterior Insula), RI (Rostral Insula) dPI (Dorsoposterior Insula), PAG (Periaqueductal 
Gray)
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Fig. 9. 
Chronic pain thalamocortical dysrhythmia is known to occur in distinct band, i.e. most 
commonly in theta, beta, and gamma bands. Work from De Ridder and Vannesste 
demonstrate p < .0001) with greatest differences found in theta-beta theta and gamma (Panel 
a), source localized to bilateral sensory discriminative pathways SI, which additional 
affective emotional pathways including dACC, sgACC, bilateral INS, bilateral PHC, and 
posterior cingulate cortex (Panel b). Pretrial and or implant characterization of chronic pain 
patient TCD could inform the practitioner of an optimal SCS paradigm, while post SCS 
TCD measures could track SCS efficacy (i.e., decrease in predominate θ theta, β beta, γ 
gamma dysrhythmias) as described by Schulman et al. (2005). dACC dorsal anterior 
cingulate cortex, sgACC subgenual anterior cingulate cortex, INS insula, PHC 
parahippocampus, SI primary somatosensory cortex, PCC posterior cingulate cortex, θ theta, 
α alpha, β beta, γ gamma. Figure adapted from Vanneste et al. (2018) Nature 
Communications (Vanneste et al., 2018)
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Fig. 10. 
Stimulation Patterns in Paresthesia and Paresthesia Free SCS Paradigms: Traditional SCS 
comprised of tonic or repetitive low frequency SCS usually in the range of 40–60 Hz 
produces paresthesia of P-SCS (a). Paresthesia free, burst spinal cord stimulation (B-SCS) 
employs incrementalincrease in amplitude with each burst. Inter-burst frequency is 40 Hz, 
while intra-burst frequency is 500 Hz (b). Between each burst there is a passive recharge 
phase. Paresthesia free high frequency SCS employs an ultra-high frequency of 10 kHz in 
continuous mode (c)
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Fig. 11. 
ECAP-SCS. Newly developed closed-loop SCS system measures evoked compound action 
potentials (ECAPs) from the spinal cord after each pulse. Greater ECAP amplitude 
represents more action potentials and is equivalent to increased fiber activation. Variable 
lead to cord contact occurs with change in position and over time. ECAP-SCS captures and 
calibrates SCS lead current to target desired ECAP waveform therefore minimizing 
variability in stimulation, which may improve clinical outcomes. ECAP-SCS is an objective 
measure of spinalcord activation that may help to predict responders to P-SCS
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Fig. 12. 
The Current literature supports multiple domains of MOA of SCS. Major P-SCS, PF-SCS 
and DRG-S analgesic MOA include modulation of 1) segmental and supraspinal 
neurotransmitters, 2) segmental and supraspinal neurophysiology/neuroplasticity, 3) central 
and peripheral neuroinflammation and 4) cortical and subcortical neurocircuits. P-SCS has 
accrued the largest literature in support of all four MOA, while only P-SCS preclinical 
studies consistently demonstrate modulation of neurotransmitters critical to analgesia. 
Emerging and published literature support the concept that all SCS paradigms (P-SCS, B-
SCS, DRG-S, HF-SCS, ECAP-SCS) contribute to altered neuronal activity (i.e. 
neurophysiological). Pre-clinical and clinical work support cortical SCS paradigms (P-SCS, 
B-SCS, DRG-S, HF-SCS, ECAP-SCS) contribute to altered neurocircuit activity
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